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INTRODUCTION 
 
Development of a formulation involves a great deal of study and 
experimental work to get optimum results. While doing so we have to keep in 
mind various factors are considered like choice of excipients, drug 
bioavailability, drug stability in required dosage form, cost effectiveness, 
manufacturing aspects. 
Now a day’s formulation research is breaking barriers of conventional 
methods. Present day’s drugs can be delivered with a convenience manner, 
performance and bioavailability. 
The oral route of drug administration is the most convenient for 
patients, with tablets emerging as the most popular solid oral dosage form 
used today. Standard compressed, controlled-release and coated tablets are 
the most common form of solid oral dosages. A wide range and diversity of 
ingredients are often included in tablet formulations. A knowledge of the 
difference between tablet and capsule formulations should enable nurses to 
improve patient compliance with respect to solid oral dosage forms. 
Oral administration is a route of administration where a substance is 
taken through the mouth. Many medications are taken orally because they are 
intended to have a systemic effect, reaching different parts of the body via the 
bloodstream. Tablets are solid dose pharmaceutical preparation containing 
drug substances usually prepared with the aid of suitable pharmaceutical 
excipients. They may vary in size, shape, weight, hardness, thickness, 
disintegration and dissolution characteristics and in other aspects, depending 
on their intended use and method of manufacture. Tablets constitute 
approximately 90% of all dosage forms clinically used to provide systemic 
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administration of therapeutic agents. This wide spread use of tablets have 
been achieved as a result of their convenience and also the diversity of tablet 
types. (Ruchita jaiswani et al.,2014)                   
Tablet is defined as a compressed solid dosage form containing 
medicaments with or without excipients. According to the Indian 
Pharmacopoeia Pharmaceutical tablets are solid, flat or biconvex dishes, unit 
dosage form, prepared by compressing a drugs or a mixture of drugs, with or 
without diluents. They vary in shape and differ greatly in size and weight, 
depending on amount of medicinal substances and the intended mode of 
administration. It is the most popular dosage form and 70% of the total 
medicines are dispensed in the form of Tablet. All medicaments are available 
in the Tablet form except where it is difficult to formulate or administer. 
Tablets are intended for oral administration. Some are swallowed whole or 
after being chewed, some are dissolved or dispersed in water before  being 
administered and some are retained on mouth where the active medicament 
is liberated.  
Solid medicaments may be administered orally as powders, pills, 
cachets, capsules or tablets. These dosage forms contain a quantity of drug 
which is given as a single unit and they are known collectively as solid unit 
dosage forms, even in the case of sustained action preparations which, 
technically, contain the equivalent of several normal doses of drug. Tablet that 
disintegrates or dissolve rapidly in the patients mouth are convenient for 
young children, elderly patients, mentally retarded and bedridden patients 
who used to suffer most probably with the problem of dysphagia and hand 
tremors. (Ruchita jaiswani et al.,2014) 
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Oral route is the most desirable and preferred method of administering 
therapeutic agents for their systemic effects, but poorly solubility of drug is 
major challenge in pharmaceutical industry.  
Up to 40% of orally administered drugs suffer from formulation 
difficulties related to their water insolubility. Dissolution rate, absorption, 
distribution and excretion of a moiety depend upon its solubility 
characteristics. Solubility is the phenomenon of dissolution of solid in liquid 
phase to give a homogenous system. Solubility is one of the important 
parameter to achieve desired concentration of drug in systemic circulation for 
pharmacological response to be shown. Poorly water soluble drugs often 
require high doses in order to reach therapeutic plasma concentrations after 
oral administration.  
Low aqueous solubility is the major problem encountered with 
formulation development of new chemical entities. Any drug to be absorbed 
must be present in the form of an aqueous solution at the site of absorption. 
Water is the solvent of choice for liquid pharmaceutical formulations. Most of 
drugs are weakly acidic and weakly basic with poor aqueous solubility. 
(Kadam S.V et al., 2013) 
The solubility is defined as a maximum quantity of solute that can 
dissolve in a certain quantity of solvent or quantity of solution at a specified 
temperature and the solubility increase bioavailability increases. (Sandeep 
Kumar et al.,2016) 
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Solubility defines as: 
Table-1. Definition of solubility 
Definition 
Parts of solvent required 
one part of solute 
Very soluble ˂1 
Freely soluble 1-10 
Soluble 10-30 
Sparingly soluble 30-100 
Slightly soluble 100-1000 
Very slightly soluble 1000-10000 
Insoluble ˃10000 
  
On the basis of solubility, drugs are classified into four classes of the 
BCS classification. Solubility challenges are faced in the Class II and Class IV 
of the BCS system. BCS classification is a scientific framework which deals in 
classification of drug substance based on its aqueous solubility and 
permeability. (Sandeep Kumar et al., 2016) 
 
Table-2. Biopharmaceutical drug classification system 
Class Solublility Permeability Examples 
I High High Metoprolol 
II Low High Neteglinide 
III High Low Cemetidin 
IV Low Low Ticagrelor 
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To improve solubility and bioavailability of poorly soluble drug we use 
various methods or techniques like solid dispersion, complexation, liquidsolid, 
hydrotropy, sonocrystallization, self-emulsifying method, micronization, 
chemical modification, pH adjustment, co‐solvency, micellar solubilization etc. 
The purpose of this review article is to describe the techniques of solubilizaton 
for the attainment of effective absorption and improved bioavailability. 
(Kadam S.V et al., 2013) 
 
FACTOR AFFECTING THE SOLUBILITY  
1. Nature of solute and solvent:  
The nature of solute and solvent depends on concentration of 
solute in specific quantity of solvent at specific temperature. 
Example: at room temperature in 100gm of water only 1gm of lead 
(II) chloride can be dissolved while 200 grams of zinc chloride can 
be dissolved.  
2. Particle size:  
Particle size affect on solubility. As article size decreases, the 
surface area to volume ratio increases. As the surface area of 
particle increases it causes greater interaction with solvent. The 
effect of particle size on solubility can be described by, 
Log (S/S0) = 
2  𝛾 𝑉
2.303 𝑅 𝑇 𝑟
 
Where,  
S is the solubility of fine particles  
S0 is the solubility of large particles  
V  is molar volume 
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ᵞ is the surface tension of the solid 
r  is the radius of the fine particle. 
T is absolute temperature 
R is gas volume  
3. Molecular size:  
Solubility affected by molecular size of particle. The solubility of the 
substance is decreased when molecules have higher molecular 
weight and higher molecular size because larger molecules are 
more difficult to surround with solvent molecules in order to solvate 
the substance.  
4. Temperature:  
Solubility affected by temperature. If the solution process absorbs 
energy then the solubility will increase with increasing temperature. 
If the solution process releases energy then the solubility will 
decrease with increasing temperature 
5. Pressure:  
For solids and liquid solutes, solubility not affected by change in 
pressure but for gaseous solutes, solubility increases as pressure 
increases and decrease as pressure decrease. 
 
SOLUBILITY ENHANCEMENT METHOD (Kadam S.V et al., 2013) 
Various techniques have been used in attempt to improve solubility and 
dissolution rates of poorly water soluble drugs. 
which include as following: 
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A. Particle Size Reduction 
B. Nanonization 
C. Cosolvency 
D. Hydrotropy 
E. pH Adjustment 
F. Sonocrystallization 
G. Supercritical Fluid (SCF) Process 
H. Solid Dispersion 
I. Inclusion Complexation 
J. Self-Emulsifying Or Self-Micro Emulsifying Systems 
K. Liquisolid Methods 
 
A. PARTICLE SIZE REDUCTION  
The solubility of drug is often intrinsically related to drug particle size; 
as a particle becomes smaller, the surface area to volume ratio increases. 
The larger surface area allows greater interaction with the solvent which 
causes an increase in solubility. Conventional methods of particle size 
reduction, such as comminution and spray drying, rely upon mechanical 
stress to disaggregate the active compound. Particle size reduction is thus 
permitting an efficient, reproducible, and economic means of solubility 
enhancement. However, the mechanical forces inherent to comminution, such 
as milling and grinding, often impart significant amounts of physical stress 
upon the drug product which may induce degradation. The thermal stress 
which may occur during comminution and spray drying is also a concern when 
processing thermo sensitive or unstable active compounds. Using traditional 
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approaches for nearly insoluble drugs may not be able to enhance the 
solubility up to desired level. 
 
B. COSOLVENCY   
The solubility of poorly soluble drugs in water can be increased by 
mixing it with some water miscible solvent in which the drug is readily soluble. 
This process is known as cosolvency and the solvent used in combination are 
known as cosolvent. Cosolvent system works by reducing the interfacial 
tension between the aqueous solution and hydrophobic solute. It is also 
commonly known as solvent blending. There is a dramatic change in the 
solubility of drugs by addition of organic co-solvent into the water. The 
cosolvents are having hydrogen acceptor or donor groups with a small 
hydrocarbon region. The hydrophobic hydrocarbon region usually interferes 
with the hydrogen bonding network of water which consequently reduces the 
intermolecular attraction of water while the hydrophilic hydrogen bonds 
ensures water solubility. Currently, the water-soluble organic solvents are 
polyethylene glycol 400 (PEG 400), ethanol, propylene glycol, and glycerin. . 
For example, Procardia (nifidipine) was developed by Pfizer contains glycerin, 
peppermint oil, PEG 400 and sodium saccharin in soft gelatin capsules. The 
water insoluble solvents include long-chain triglycerides (i.e. peanut oil, corn 
oil, soybean oil, sesame oil, olive oil, peppermint oil, hydrogenated vegetable 
oil and hydrogenated soybean oil), medium-chain triglycerides (Miglyol 812), 
beeswax, d-α- tocopherol (vitamin E) and oleic acid. 
 
C. SURFACTANTS 
Conventional approach to solubilize a poorly soluble substance is to 
reduce the interfacial tension between the surface of solute and solvent for 
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better wetting and salvation interaction. A wide variety of surfactants like 
Polyglycolized glyceride, Tweens, Spans, Polyoxyethylene stearates and 
synthetic block copolymers like Poly (propylene oxide)-poly (ethylene oxide)- 
poly (propylene oxide) like Poloxamers based micelles, Poly (beta-benzyl-L-
aspartate)-b-poly (ethylene oxide), Poly (caprolactone)-b-poly (ethylene oxide) 
etc are very successful as excipient and carrier for dissolution enhancement. 
Improvement of drug solubility by using the amphiphilic surfactants is due to 
lowering surface tension between drug and solvent, improvement of wetting 
characteristics and micellar solubilization. 
D. POLYMERIC ALTERATION:  
Different crystalline forms of a drug that may have different properties 
are known as Polymorphs. Polymorphs may differ in physicochemical 
properties such as physical and chemical stability, shelf-life, melting point, 
vapor pressure, intrinsic solubility, dissolution rate, morphology, density and 
biological activities as well as bioavailability. Amongst the stable, unstable and 
metastable crystalline polymorphs, metastable forms are associated with 
higher energy with increased surface area, subsequently solubility, 
bioavailability and efficacy. With regard to bioavailability, it is preferable to 
change drug from crystal forms into metastable or amorphous forms. 
However, the possibility of a conversion of the high energy amorphous or 
metastable polymorph into a low energy crystal form having low solubility 
cannot be ruled out during manufacture and storage. It is preferable to 
develop the most thermodynamically stable polymorph of the drug to assure 
reproducible bioavailability of the product over its shelf-life under a variety of 
real-world storage conditions.  
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E. SOLID DISPERSION METHOD (Kadam S.V et al., 2013) 
Solid dispersion technology is the science of dispersing one or more 
active ingredients in an inert matrix in the solid stage to achieve an increased 
dissolution rate or sustained release of drug, altered solid state properties and 
improved stability.  
 
CLASSIFICATION OF SOLID DISPERSION  
Solid dispersion classified in 3 groups; 
 First generation solid dispersions: In first generation solid dispersion, 
formulation of eutectic mixtures or molecular dispersion improved the 
rate of drug release which in turn increases the bioavailability of poorly 
water soluble drugs. Disadvantage related formulation of crystalline solid 
does not release drug quickly. Example: Crystalline carriers: Urea, 
Sugars and Organic acids. 
 Second generation solid dispersion: In second generation we use 
amorphous state of carrier which improves drug release; likes fully 
synthetic polymers include povidone (PVP), polyethyleneglycols (PEG) 
and polymethacrylates. Natural product based polymers are mainly 
composed by cellulose derivatives, such as hydroxypropyl 
methylcellulose (HPMC), ethylcellulose or hydroxypropyl cellulose or 
starch derivates, like cyclodextrins. 
 Third generation solid dispersion:  
In third generation we use carrier which have surface activity and self 
emulsifying property. The surfactants decrease the recrystallisation of 
drug and thus improve the solubility of drug. Example: Surface active 
self-emulsifying carriers: Poloxamer 408, Tween 80, and Gelucire 44/14. 
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MECHANISM OF SOLUBILITY ENHANCEMENT 
a) Particles with Reduced Particle Size                                                                                                                                                                                
Preparation of solid dispersions results in particles with reduced 
particle size and thus the surface area is improved and increased dissolution 
rate is attained. The ultimate result is improved bioavailability.        
             
b) Particles with Improved Wettability 
Wettability is improved during solid dispersion production. It has been 
suggested that the presentation of particles to the dissolution medium as 
physically separate entities may reduce aggregation. In addition, many of the 
carriers used for solid dispersions may have some wetting properties; hence, 
improved wetting may lead to reduced agglomeration and increased surface 
area. 
 
c) Particles with Higher Porosity 
Particles in solid dispersions have been found to have a higher degree 
of porosity. The increase in porosity also depends on the carrier properties; 
for instance, solid dispersions containing linear polymers produce larger and 
more porous particles than those containing reticular polymers and, therefore, 
result in a higher dissolution rate. The increased porosity of solid dispersion 
particles also hastens the drug release profile. 
 
d) Drugs in Amorphous State:  
Poorly water-soluble crystalline drugs, when in the amorphous state 
tend to have higher solubility. Drug in its amorphous state shows higher drug 
release because no energy is required to break up the crystal lattice during 
the dissolution process. In solid dispersions, drugs are presented as 
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supersaturated solutions after system dissolution, and it is speculated that, if 
drugs precipitate, it is as a metastable polymorphic form with higher solubility 
than the most stable crystal form.  
 
e) Solubilization Effect:  
The carrier material, as it dissolves, may have a solubilization effect on 
the drug. Enhancement in solubility and dissolution rate of poorly soluble 
drugs is related to the ability of carrier matrix to improve local drug solubility 
as well as wettability 
 
SELECTION OF CARRIER: 
One of the most important steps in the formulation and development of 
solid dispersion for various applications is selection of carrier. The properties 
of carrier have a major influence on dissolution characteristics of the drug. A 
material should possess following characteristics to be suitable carrier for 
increasing dissolution. 
 Freely water soluble with intrinsic rapid dissolution properties. 
 Non-toxic and pharmacologically inert 
 Thermal stability preferably with low melting point especially for melt 
method 
 Solubility in variety of solvents and should pass through a vitreous 
state upon solvent evaporation for the solvent method. 
 Ability to increase aqueous solubility of drug. 
 Chemical compatibility and not forming a strongly bonded complex with 
drug. 
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POLYMERS USED IN SOLID DISPERSIONS 
A variety of polymers is offered as carriers for formulation of solid 
dispersion. Table 2.1 represents various categories and examples of carriers. 
Some polymers used in solid dispersions are as follows:  
 
A) Polyethylene glycol (PEG): 
The term polyethylene glycols refer to compounds that are obtained by 
reacting ethylene glycol with ethylene oxide. PEGs are commonly termed as 
polyethylene oxides, with a molecular weight (MW) usually falling in the range 
200-3,00,000. For the manufacture of solid dispersions and solutions, PEGs 
with molecular weights of 1500-20,000 are usually employed. As the MW 
rises, so does the viscosity of the PEG. At MW of up to 600, PEGs are fluid, in 
the range 800 -1500 they have a consistency that is best described as 
vaseline-like, from 2000 to 6000 they are waxy and those with MW of 20,000 
and above form hard, brittle crystals at room temperature. Their solubility in 
water is generally good, but reduces with MW. A meticulous advantage of 
PEGs for the solid dispersions is that they have good solubility in numerous 
organic solvents. The melting point of the PEGs of interest lies under 65 0C in 
every case (e.g. the m.p. of PEG 1000 is 30-400C, the m.p. of PEG 4000 is 
50- 580C and the m.p.of PEG 20,000 is 60-630C .Additional attractive features 
of the PEGs include their ability to solubilise some compounds and also to 
improve compound wettability. Even the dissolution rate of a relatively soluble 
drug like aspirin can be improved by formulating it as a solid dispersion in 
PEG 6000. 
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B) Polyvinyl Pyrrolidone (PVP):  
PVPs have molecular weights ranging from 10,000 to 700,000. It is 
soluble in solvents like water, ethanol, chloroform and isopropyl alcohol. PVP 
is not suitable for preparation of solid dispersions prepared by melt method 
because it melts at a very high temperature above 275ºC, where it gets 
decomposed.   
 
C) Polymers and Surface Active Agent Combinations:  
The addition of surfactants to dissolution medium lower s the interfacial 
tension between drug and dissolution medium and promotes the wetting of 
the drug thereby they enhance the solubility and dissolution of drug. Ternary 
dispersion systems have higher dissolution rates than binary dispersion 
systems.  
 
D) Cyclodextrins:  
Cyclodextrins are primarily used to enhance solubility, chemical 
protection, taste masking and improved handling by the conversion of liquids 
into solids by entrapment of hydrophobic solute in hydrophilic cavity of CD. 
Advantages of CD include increasing the stability of the drug, release profile 
during gastrointestinal transit through modification of drug release site and 
time profile, decreasing local tissue irritation and masking unpleasant taste.  
 
E) Phospholipids:  
Phospholipids are major structural components of cell membranes. 
Phosphotidylcholine was first isolated from egg yolk and brain. In phosphatidyl 
ethanolamine and phosphatidyl serine, the choline moiety is replaced by 
ethanolamine and serine respectively. Other phospholipids that occur in 
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tissues include phosphotidyl ethanolamide, phosphotidyl serine and 
phosphotidyl glycerol. Naturally occuring lecithins contain both a saturated 
fatty acid and unsaturated fatty acids with some exceptions.  
 
Methods of preparation of solid dispersions 
Various methods used for preparation of solid dispersion system. 
These methods are given bellow. 
1. Melting method 
2. Solvent method 
3. Melting solvent method (melt evaporation) 
4. Melt extrusion methods 
5. Lyophilization techniques 
6. Melt agglomeration Process 
7. The use of surfactant 
8. Electrospinning 
9. Super Critical Fluid (SCF) technology 
 
1. Melting method 
The melting or fusion method is the preparation of physical mixture of a 
drug and a water-soluble carrier and heating it directly until it melted. The 
melted mixture is then solidified rapidly in an ice-bath under vigorous stirring. 
The final solid mass is crushed, pulverized and sieved.  
 
2. Solvent method 
In this method, the physical mixture of the drug and carrier is dissolved 
in a common solvent, which is evaporated until a clear, solvent free film is left. 
The film is further dried to constant weight. The main advantage of the solvent 
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method is thermal decomposition of drugs or carriers can be prevented 
because of the relatively low temperatures required for the evaporation of 
organic solvents 
 
3. Melting solvent method (melt evaporation) 
It involves preparation of solid dispersions by dissolving the drug in a 
suitable liquid solvent and then incorporating the solution directly into the melt 
ofpolyethylene glycol, which is then evaporated until a clear, solvent free film 
is left. The film is further dried to constant weight. The 5 –10% (w/w) of liquid 
compounds can be incorporated into polyethylene glycol 6000 without 
significant loss of its solidproperty. It is possible that the selected solvent or 
dissolved drug may not be miscible with the melt of the polyethylene glycol. 
Also the liquid solvent used may affect the polymorphic form of the drug, 
which precipitates as the solid dispersion. This technique possesses unique 
advantages of both the fusion and solvent evaporation methods. From a 
practical standpoint, it is only limited to drugs with a low therapeutic dose e.g. 
below 50 mg. 
 
ADVANTAGES OF SOLID DISPERSIONS: 
Generally, solid dispersion is mainly used 
 To reduced particle size. 
 To improve wettability. 
 To improve porosity of drug. 
 To decrease the crystalline structure of drug in to amorphous 
form. 
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 To improve dissolvability in water of a poorly water-soluble drug 
in a pharmaceutical. 
 To mask the taste of the drug substance. 
 To prepare rapid disintegration oral tablets. 
 To obtain a homogenous distribution of small amount of drugs at 
solid state. 
 To stabilize unstable drugs. 
 To dispense liquid or gaseous compounds. 
 To formulate a faster release priming dose in a sustained 
release dosage form. 
 To formulate sustained release dosage or prolonged release 
regimens of soluble drugs using poorly soluble or insoluble 
carriers 
 
 
 
 
CHAPTER II 
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SUBLINGUAL TABLETS – A REVIEW 
 
Drugs have been applied to the mucosa for topical application for many 
years. However, recently there has been interest in exploiting the oral cavity 
as a portal for delivering drugs to the systemic circulation. 
Drug delivery through the sublingual route had emerged from the 
desire to provide rapid onset of pharmacological effect. Dysphasia (difficulty in 
swallowing) is a common problem of all age groups, especially geriatrics, 
pediatric, and patients who are mentally retarded, uncooperative, nauseated 
or on reduced liquid intake/diets have difficulties in swallowing these dosage 
forms. Sublingual drugs are administered under the tongue and reached 
directly in to the systemic circulation through the ventral surface of the tongue 
and floor of the mouth. The drug is rapidly absorbed into the reticulated vein 
that lies underneath the oral mucosa, and transported through the facial veins, 
internal jugular vein, and braciocephalic vein and then drained in to systemic 
circulation. Considering the oral cavity sublingual area is the most permeable 
part of the buccal cavity. The decreasing order of permeability in the buccal 
cavity is the sublingual, the buccal area (cheek), then the palatal area. The 
order is generally based upon the relative thickness and the extent of blood 
supply to the specific part. (Patil Vaishali A et al., 2015) 
The sublingual route usually produces a faster onset of action than the 
orally ingested tablets and the portion absorbed through the sublingual blood 
vessels bypasses the hepatic first‐pass metabolic processes 
The sublingual tablets are usually small and flat, compressed lightly to 
keep them soft. The tablets must dissolve quickly allowing the API to be 
absorbed quickly and It is designed to dissolve in small quantity of saliva; after 
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the tablet is placed in under the tongue, the patient should avoid eating, 
drinking, smoking and possibly talking in order to keep the tablet in place. 
Systemic drug delivery through the sublingual route had emerged from the 
desire to provide immediate onset of pharmacological action. 
Sublingual products have been designed for numerous indications 
ranging from migraine (for which rapid onset of action is important) to mental 
illness(for which patient compliance is important for treating chronic 
indications such as depression and schizophrenia) . Sublingual route provides 
3-10 times greater absorption of the drug than oral route and is only 
surpassed by hypodermic injection. Sublingual route is very much appropriate 
for short-acting drugs. 
Most of the sublingual drugs, which are absorbed by simple diffusion; 
here the sublingual area acts like a litmus paper readily soaking up the 
substances; however not all the substances are permeable and accessible to 
oral mucosa. Majority of drugs which are administered through sublingual 
route falls in the category of antianginal drug. Systemic drug delivery through 
the sublingual route had emerged from the desire to provide immediate onset 
of pharmacological effect.  
By selecting the appropriate pharmaceutical excipients in the correct 
proportion, in combination with optimal manufacturing techniques the 
sublingual tablets could be prepared effectively. 
 
ORAL MUCOSA 
 The oral mucosal lining offers a preferable route for the local and 
systemic administration of certain drugs and for the treatment of some 
diseases. This route has several distinct advantages over the enteral and 
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parenteral routes of drug delivery due to its rich blood supply, rapid onset of 
action, enhanced bioavailability, avoidance of the first pass and food effects, 
increased patient compliance, and ease of self-medication. 
Oral mucosal drug absorption is governed by (a) the permeability of the 
oral mucous membrane and the anatomy of the underlying tissues, (b) the 
physicochemical properties of the drugs, and (c) the formulation design. The 
focus of this review is on the latter two points, as an understanding of these 
elements enables the selection of drug candidates suitable for oral mucosal 
delivery and optimizes drug delivery.  
 
ANATOMICAL STRUCTURE OF THE ORAL MUCOSA 
 
 
Figure-1: Anatomical structure of oral mucosa 
 
The oral cavity has four distinct regions that can absorb drugs through 
the sublingual, buccal, gingival, and palatal regions. These regions differ from 
one another in histological structure and biochemical composition of the 
mucosal membrane, and their ability to retain the dosage form long enough to 
allow complete drug absorption. The sublingual membrane on the floor of the 
CHAPTER II                                           SUBLINGUAL TABLET – A REVIEW 
 
Dept of Pharmaceutics, College of Pharmacy, MMC, Madurai-20 Page 21 
mouth under the tongue and the buccal membrane lining the cheeks are 
commonly used for systemic drug delivery. 
The mucosal lining consists of three distinct layers. The outermost 
layer is the epithelial membrane, which consists of stratified squamous 
epithelial cells and has a protective barrier function. The innermost layer of 
the epithelial membrane is called the basement membrane that replenishes 
the epithelium. Below the epithelium lies the lamina propria followed by the 
submucosa. The lamina propria is a hydrated and less dense layer of 
connective tissue containing collagen and elastic fibers. The oral submucosa 
is also richly supplied with blood vessels. 
 
SUBLINGUAL GLANDS  
 
Figure-2: Sublingual glands 
 
Salivary glands which are present in the floor of the mouth underneath 
the tongue. They are also known as sublingual glands. They produce mucin in 
turn produces saliva. The interior area of the mouth remains lubricated due to 
production of the saliva by the glands, which is necessary for chewing and 
food swallowing. The fluid which is produced by the glands gets mix with the 
food, so the food gets easily chewed. Due to low secretion of the saliva it can 
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create problem in swallowing the food and potential for food lodge in the 
throat increases. The absorption is transfer of the drug from its site of 
administration into systemic circulation, so it can be said that absorption is 
directly proportional layer thickness.  
The absorption of the drug following this way Sublingual > Buccal > 
Gingival >Palatal. Due to high permeability and rich blood supply, the 
sublingual route can produce rapid onset of action so the drug with short 
delivery period can be delivered and dose regimen is frequent. The drug gets 
diluted in the saliva and from there the drug is adsorbed across the oral 
cavity. For example: Glyceryl nitrate-a potent coronary vasodilator which is 
used for rapid symptomatic relief of angina. After administration, its gets 
pharmacologically active after 1-2 minutes. Oral spray was found to provide 
rapid relief of symptom with first class metabolism. The extent of first class 
metabolism when compared to the sublingual spray decreased to 48% with 
sublingual tablets and 28% with the oral dose. ( Neha Narang et al., 2011) 
 
MECHANISM OF SUBLINGUAL ADMINISTRATION: 
Following sublingual administration, the drugs are absorbed across the 
mucous membrane by one of the following mechanisms: 
 Passive diffusion 
 Active or carrier-mediated transport 
 Endocytosis. 
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Figure-3: Mechanism of drug absorption 
 
Although the process of passive diffusion is spontaneous, the rate of 
diffusion is dependent on the molecular weight and solubility of the drug, 
concentration gradient, temperature, the surface area of the membrane, and 
the proximity of the molecule to the membrane. When a drug exists in its 
unionized form in saliva, it is absorbed by passive diffusion. Physical models 
have been proposed to describe drug absorption from saliva through the lipid 
bilayer of the mucous membrane into systemic circulation. The rate of drug 
absorption across the mucous membrane is directly related to its partition 
coefficient. Some compounds, such as glutamic acid, L-ascorbic acid, 
nicotinic acid, and thiamine, are transported via a carrier-mediated process. 
The absorption is effected by the lipid solubility and hence the 
permeability of the solution commonly known as osmosis, the ionization, and 
the molecular weight of the drug. The cells of oral epithelium adsorb the drug 
by the process of endocytocis. It is unlikely that the same mechanism is 
observed throughout the stratified epithelium. However, it is believed that 
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acidic stimulation of the salivary glands, with the accompanying 
vasodilatation, facilitates absorption and uptake into the circulatory system.  
The mouth is lined with a mucous membrane which is covered with 
squamous epithelium and contains mucous glands. The sublingual mucosal 
tissue is similar to that of buccal mucosa. The salivary glands consist of 
lobules of cells which secrete saliva through the salivary ducts into the mouth.  
The three pairs of salivary glands are the parotid, the submandibular 
and the sublingual which lies on the floor of the mouth. The more acidic the 
taste is, greater the stimulation of salivary output; serving to avoid potential 
harm to acid‐sensitive tooth enamel by bathing the mouth in copious 
neutralizing fluid. The sublingual artery travels forward to the sublingual gland, 
it supplies the gland and branches to the neighboring muscles and to the 
mucous membranes of the mouth, tongue and gums. Two symmetrical 
branches travel behind the jawbone under the tongue to meet and join at its 
tip. Another branch meets and anastomoses with the submental branches of 
the facial artery. The sublingual artery stems from the lingual artery – the 
body's main blood supply to the tongue and the floor of the mouth – which 
arises from the external carotid artery. The proximity with the internal carotid 
artery allows fast access to its route supplying the greater part of the cerebral 
hemisphere.  
Lipids present in the oral mucous membrane offer the main barrier to 
the permeability of hydrophilic drugs. On the other hand, well-hydrated 
connective tissues provide resistance to lipophilic drugs. Thus, the potential 
transport path across the oral mucous membrane may be either polar or non-
polar. Non-polar molecules cross through the lipid regions of the epithelium, 
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while polar molecules travel through ionic channels present in the intercellular 
spaces of the epithelium, or aqueous pores present in the epithelial cells. For 
this reason, an understanding of a drug’s lipophilic or hydrophilic nature 
during the developmental stage of the drug product appears to be the most 
useful index for evaluating its suitability for absorption across the oral mucosa. 
permeation and diffusion, and so are able to move freely between the tissues 
of the body. Active transportation into cells leads to rapid metabolisation of the 
substances. Molecules such as glucose (fructose) and amino acids are 
essential for cell metabolism and special mechanisms have evolved to 
facilitate their rapid diffusion and permeation across cell membranes. (Neha 
Narang et al., 2011) 
 
SUITABILITY OF DRUG FOR PREPARATION OF SUBLINGUAL TABLET  
 No bitter taste.  
 Dose lowers than 20 mg, e.g. nifedipine.  
 Small to moderate molecular weight.  
 Good stability in water and saliva.  
 Partially no ionized at the oral cavities pH.  
 Under going first pass effect e.g. ketotifen fumarate. 
 Many drug properties could potentially affect the performance of 
sublingual tablets like solubility, crystal morphology, particle size, 
hygroscopicity, compressibility and bulk density of drug.  
 Some drugs undergoes extensive first pass metabolism which results 
in poor bioavailability of its oral dosage forms, that kind of drugs are 
suitable for sublingual dosage form.  
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 Drugs that are unstable in parenteral preparation are suitable for 
sublingual dosage form.    
 Many pharmaceuticals are designed for sublingual administration, 
including cardiovascular drugs, steroids, barbiturates, enzymes, 
antiemetics, vitamins, minerals and vaccines Able to saturate the oral 
mucosa.  
 Should have lower bio availability are good candidates for sublingual 
tablets 
 Frequent dosing of drugs unsuitable for sublingual tablets. 
 Ability to permeate oral muosa.  
 
FACTORS AFFECTING THE SUBLINGUAL ABSORPTION  
(Somya Sah et al., 2016) 
 Lipophilicity of drug: For a drug to be absorbed completely through 
sublingual route, the drug must have slightly higher lipid solubility than 
that required for GI absorption is necessary for passive permeation.  
 Solubility in salivary secretion: In addition to high lipid solubility, the 
drug should be soluble in aqueous buccal fluids i.e. biphasic solubility 
of drug is necessary for absorption.  
 pH and pKa of the saliva: As the mean pH of the saliva is 6.0, this pH 
favors the absorption of drugs which remain unionized. Also, the 
absorption of the drugs through the oral mucosa occurs if the pKa is 
greater than 2 for an acid and less than 10 for a base.  
 Binding to oral mucosa: Systemic availability of drugs that bind to 
oral mucosa is poor.  
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 Thickness of oral epithelium: As the thickness of sublingual 
epithelium is 100‐200 μm which is less as compared to buccal 
thickness. So the absorption of drugs is faster due to thinner epithelium 
and also the immersion of drug in smaller volume of saliva.  
 
IDEAL CHARACTERISTICS OF SUNLINGUAL TABLETS  
MOUTH FEEL 
Mouth-feel is critical, and patients should receive a product that feels 
pleasant. Any large particles   from the disintegrating tablet that are insoluble 
or slowly soluble in saliva would lead to an unpleasant gritty feeling. This can 
be overcome by keeping the majority of the particles below the detectable 
size limit. In some cases, certain flavors can improve mouth-feel perception, 
resulting in a product that is perceived as being less gritty, even if the only 
change is the flavor.  Effervescence can be added to aid disintegration and 
improve mouth-feel by reducing the “dryness” of a product. 
 
HYGROSCOPICITY 
Several fast dissolving dosage forms are hygroscopic and cannot 
maintain physical integrity under normal conditions of temperature and 
humidity. Hence they need protection from humidity, which calls for 
specialized product packaging. 
 
FRIABILITY 
In order to allow fast dissolving tablets to dissolve in the mouth, they 
are made of either very porous or soft molded matrices or compressed into 
tablets with very low compression force, which makes the tablets friable 
and/or brittle which are difficult to handle, often requiring specialized peel off 
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blister packing. To overcome this problem, some companies introduced more 
robust forms of fast dissolving tablets, such as Wowtab by Yamanouchi 
Shadlee and Dura Solve by CIMA labs. 
 
DRUG SELECTION CRITERIA 
 Able to saturate the oral mucosa. 
 At least moderately non-ionized at oral cavity PH. 
 Have the ability to diffuse and partition into the epithelium of upper GIT. 
 Small to moderate molecular weight. 
 Low dose drugs mostly less than 20 mg. 
 Should have good stability in saliva and water. 
 Should have lower bio availability are good candidates for sublingual 
tablets. 
 Frequent dosing drugs are unsuitable for sublingual tablets. 
 Ability to permeate oral mucosal tissue 
 
Advantages  
 Rapid onset of action is achieved as compared to the oral route.  
 Liver is bypassed and also drug is protected from metabolism due to 
digestive enzymes of the middle gastro intestinal tract  
 Improved patient compliance due to the elimination of associated pain 
with injections; administration of drugs in unconscious or incapacitated 
patients; convenience of administration as compared to injections or 
oral medications.  
 Low dosage gives high efficacy as hepatic first pass metabolism is 
avoided and also reduces the risk of side effects.  
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 The large contact surface of the oral cavity contributes to rapid and 
extensive drug absorption.  
 Due to rapidity in action these sublingual dosage forms are widely 
used in emergency conditions e.g. asthma.  
 Rapid absorption and higher blood levels due to high vascularization 
of the  region and therefore particularly useful for administration of 
antianginal drugs.  
 They also present the advantage of providing fast dissolution or 
disintegration in the oral cavity, without the need for water or chewing.  
 
Disadvantages  
 Since sublingual administration of drugs interferes with eating, 
drinking, and talking, this route is generally considered unsuitable for 
prolonged administration.  
 Although this site is not well suited to sustained‐delivery systems.  
 Sublingual medication cannot be used when a patient is 
uncooperative.  
 The patient should not smoke while taking sublingual medication, 
because smoking causes vasoconstriction of the vessels. This will 
decrease the absorption of the medication.  
 Various types of sublingual dosage forms are available but tablets, 
films and sprays are in trends these days. For the preparation of 
these dosage forms different methods are described depends upon 
the feasibility and advantages over the others.  
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Requirements of sublingual tablets 
 Rate of absorption from the saliva solution  
 Drug and dosage form stability 
 Mechanical strength of final product 
 Taste, mouth feel, swallowing ability 
 Exhibit low sensitivity to environmental conditions such as humidity 
and temperature 
 Allows the manufacture of tablet using conventional processing and 
packaging equipment at low cost 
 Overall bioavailability  
 Require no water for oral administration, yet dissolve/disintegrate in 
mouth in a matter of seconds 
 Leave minimal or no residue in mouth after administration. 
 
TECHNIQUES FOR PREPARATION OF SUBLINGUAL TABLETS  
(Somya Sah et al. 2016) 
The formulation of sublingual tablets involves the selection of suitable 
excipients of bland taste that shall ultimately resulting in a rapid disintegrating 
tablet their by enhancing the dissolution of active ingredient. There are 
different types of techniques used for preparation of sublingual Tablets. 
 
1. COMPRESSION MOLDING: 
Tablets manufactured by the compression molding process exhibit 
rapid disintegration and dissolution, which is usually within 5–10 seconds. 
These tablets pose special challenges during handling and shipping, because 
of the poor mechanical strength, and may require special packaging. 
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Alternatively, the mechanical strength of the tablets may be enhanced by 
employing a suitable binder. However, the binder level should be optimized to 
avoid any deleterious effects on disintegration and dissolution of the tablets. 
The formulations for the compression molding process typically contain 
soluble excipients to impart quick and complete dissolution, and taste 
modifiers for patient compliance. Molded tablets have also been prepared 
directly from a molten matrix, in which the drug is dissolved or dispersed (heat 
molding), or by evaporating the solvent from a drug solution or suspension at 
room pressure (no vacuum lyophilization). 
The compression molding process involves moistening of the 
formulation blend with a solvent (usually hydro-alcoholic), followed by molding 
into tablets under low pressure. The moist tablets are finally dried. The lower 
compression pressure employed for molding and drying of the moist tablet 
produces a highly porous tablet structure with enhanced dissolution. The 
choice, ratio, and amount of granulating solvents are critical to the 
physicochemical characteristics, performance, and stability of the tablets, and 
should be optimized. Several patented technologies are also available for 
commercial manufacture of compression molded tablets. 
 
2. DIRECT COMPRESSION: 
The direct compression method is commonly used for commercial 
manufacture of sublingual tablets. It is a simple and cost-effective process, as 
it employs ingredients that can be mixed well and do not require further 
granulation steps prior to lubrication and compression. Sublingual tablets 
manufactured by the direct compression method exhibit good mechanical 
strength and acceptably fast disintegration. 
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The directly compressible sublingual tablet formulation contains directly 
compressible soluble excipients, a super disintegrant, and lubricant. It may 
also contain microcrystalline cellulose, dry binder, buffers, surface-active 
agents, sweeteners, and flavors. Sugar-based excipients are widely used as 
bulking agents because of their high aqueous solubility, sweetness, pleasant 
feeling in the mouth, and good taste-masking. Nearly all sublingual 
formulations incorporate some saccharide-based material. The choice of a 
suitable disintegrant and its amount are critical for achieving a fast 
disintegration and dissolution rate. Sometimes effervescent agents are used 
to increase disintegration and dissolution of sublingual tablets. 
Several novel approaches of incorporating disintegrants and other 
soluble and/or insoluble excipients to obtain rapid dissolution and adequate 
mechanical strength are reported. One example is the Flashtab technology of 
multiparticulate actives (coated crystals and uncoated or coated 
microgranules). In these tablets, the simultaneous presence of a disintegrant 
with a high swelling or disintegrating force, defined as “disintegrating agent,” 
and a substance with a low swelling force (starch, cellulose, and direct-
compression sugar), defined as “swelling agent,” was claimed as the key 
factor for the rapid disintegration of a tablet. The tablet manufactured by this 
technology is reported to have adequate mechanical strength.  
 
Advantages 
 Low labor input 
 A dry process 
 Fewest processing steps. 
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Disadvantages 
 Stratification may occur due to differences in particle size and bulk 
density which results poor content uniformity. 
 A large dose drug may cause problem in direct compression. It 
requires diluents. The tablet becomes large in size which is difficult 
to swallow and also costly. 
 During handling of dry materials static charge may form which may 
present uniform distribution of drug. 
 Direct compression diluents may interact with the drug. For 
example, amine drug with Lactose produce discoloration of tablet. 
 
3. FREEZE DRYING (LYOPHILIZATION): 
The process of freeze drying (lyophilization) is expensive, time-
consuming, and produces tablets of poor mechanical strength. For these 
reasons, it is not commonly used to manufacture sublingual tablets. However, 
it does have advantages over the other processes, as the tablets made by this 
process have high porosity, and when placed under the tongue disintegrate 
and dissolve immediately. It is a process of choice for products that are 
unstable or are heat sensitive. The process involves lowering the temperature 
of the product in an aqueous medium to below freezing, followed by applying 
a high-pressure vacuum. To extract the water in the form of a vapor, which is 
collected as ice on a condenser, a gradual temperature rise is applied during 
the drying process. The product temperature at the ice sublimation interface 
and the formulation collapse temperature are critical to obtain a freeze-dried 
cake of quality structure. This process retains the physical structure and 
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preserves the material for storage or transport.The resulting tablets are 
usually light and have highly porous structures that allow rapid dissolution or 
disintegration. The freeze-drying process may result in a product with an 
amorphous structure, leading to an enhanced dissolution rate. However, 
tablets manufactured by freeze drying process have poor stability at a higher 
temperature and humidity. 
4. SPRAY DRYING:  
In spray drying process, highly porous and fine powder can be 
produced and processing solvent is evaporated during process. Spray dryers 
are widely used in pharmaceuticals and biochemical process. Spray drying 
can be used to prepare rapidly disintegrating tablets by using support matrix 
such as hydrolyzed and non hydrolyzed gelatin  and other components like 
Mannitol as bulking agent, sodium starch glycolate, Crosscarmellose sodium 
as disintegrants, acidic material like citric acid and alkali like sodium 
bicarbonate to enhance disintegration and dissolution. The tablet 
manufactured from this process, disintegrated in less than 20 seconds in an 
aqueous medium. 
 
Figure-4: Spray Drying Process 
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5. SUBLIMATION:  
 The key to rapid disintegration for mouth dissolving tablet is the 
presence of a porous structure in the tablet matrix. Conventional compressed 
tablet that contain highly water-soluble ingredients often fail to dissolve rapidly 
because of low porosity of the matrix. Hence, to generate porous matrix, 
volatile ingredients are used that are later subjected to a process of 
sublimation. The volatile material was then removed by sublimation and that 
result in formation of a porous matrix (approximately 30%). 
 
Figure-5: Sublimation process 
6. MASS EXTRUSION:  
 This technology involves softening of the active blend using the 
solvent mixture of water soluble polyethylene glycol and methanol and 
expulsion of softened mass through the extruder or syringe to get a 
cylindrical shaped extrude which are finally cut into even segments using 
heated blade to form tablets. This process can also be used to coat 
granules of bitter drugs to mask their taste. 
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7. DISINTEGRATE ADDITION:  
 Disintegrate addition technique is one popular technique for 
formulating Fast-dissolving tablets because of its easy implementation and 
cost-effectiveness. The basic principle involved in formulating Fast-
dissolving tablets by disintegrates addition technique is addition of 
superdisintegrants in optimum concentration so as to achieve mouth 
dissolving along with the good mouth feel. 
 
Mechanism of Superdisintegrants 
There are four main mechanisms for tablets disintegration as follows 
 
1. Swelling 
 The most accepted general mechanism of action for tablet 
disintegration is swelling. The tablets with high porosity nature show poor 
disintegration due to have lack of adequate swelling force. On the other hand, 
sufficient swelling force is exerted in the tablet with low porosity. Note if the 
packing fraction is very high, fluid is unable to penetrate in the tablet and 
disintegration is again slows down. 
 
2. Porosity of capillary action (Wicking) 
 Disintegration by capillary action is always the first step. When we put 
the tablet into suitable aqueous medium, the medium penetrates into the 
tablet and replaces the air adsorbed on the particles, which weakens the 
intermolecular bond and breaks the tablet into fine particles. The water up 
take by tablet mainly depends upon hydrophilicity of the drug/excipients and 
tableting conditions. 
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3. Disintegrating particle due to repulsive forces 
 The another mechanism of tablet disintegration attempts to explain the 
swelling of tablet made with ‘non-swellable’ disintegrants. Particle repulsion 
theory based on the observation that non swelling particle also cause 
disintegration of tablets. Water is required for The electric repulsive forces 
between particles are the mechanism of disintegration. Wicking is secondary. 
4. Due to deformation 
 During tablet compression, disintegrated particles get deformed and 
these deformed particles get into their normal structure when they come in 
contact with aqueous media or water. The swelling capacity of starch was 
improved when granules were extensively deformed during compression. This 
increase in size of the deformed particles produces a breakup of the tablet. 
COMERCIALLY AVAILABLE SUBLINGUAL TABLETS 
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LITERATURE REVIEW 
Siji C et al (2018) prepared carvedilol sublingual tablets which is an 
oral antihypertensive agent by direct compression using different 
superdisintegrants like crosscarmellose sodium, crosspovidone, sodium 
starch glycolate and the solubility enhanced by solid dispersion method. 
Prepared tablets evaluated for thickness, uniformity of weight, hardness, 
friability, wetting time, invitro disintegration time, drug content, invitro drug 
release. The formulation F7 consist of superdisintegrant crosscarmellose 
sodium 5% and drug polymer in the ratio 1:4 shows the maximum drug 
release. 
Harmanpreet singh et al (2017) prepared rizatriptan sublingual 
tanblets by direct compression method using different bioadhesive polymers 
such as sodium carboxy methyl cellulose, HPMC-K4M and chitosan at various 
concentration ranging from 0.5-5% w/w along with sodium starch glycolate or 
cross carmellose sodium as superdisintegrants at different concentration 
ranging 2-8% w/w. The formulation batches containing 2% w/w chitosan along 
with 2% w/w sodium starch glycolate or cross carmellose sodium which 
disintegrate rapidly and slow high dissolution and ex vivo permeation. From 
this the formulation showed increased the bioavailability and directly enter into 
the systemic circulation. 
Wafa Al Madhagi et al (2017) prepared glimepiride sublingual tablets 
gives rapid drug absorption that can be used in emergency. The were 
prepared by using different superdisintegrants like sodium starch glycolate, 
cross povidone, cross carmellose sodium, pre-gelatinized starch, maize 
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starch. The formulations contain binders like flulac and aerosil with 
disintegration time 21 seconds give the suitable sublingual tablets. 
Saroj Makwana et al (2017) developed sublingual tablets of 
nicardipine hydrochloride used for the treatment of angina and it having low 
bioavailability about 10-40% orally attributed to the hepatic first pass 
metabolism. The solubility of nicardipine enhanced by carried solid dispersion 
of drug and beta cyclodextrin complex. The sublingual tablets were prepared 
direct compression method by using sodium starch glycolate, cross 
carmellose sodium, cross povidone as superdisintegrants. The optimized 
formulation showed in-vitro disintegration time was 41 seconds and 99.95% 
drug release within the 8 minutes. Formulation containing 4% crosspovidone 
and 2% PVP K-30 show highest disintegration time and ex-vivo permeation 
was 96.81% within the 14 minutes. 
Bhanja SB et al (2017) developed a sublingual tablet of Perindopril 
which is an effective drug in the treatment of hypertension. Perindopril 
containing tablets were prepared by direct compression method using 
different ingredients such as Crospovidone, Sodium saccharin, Mannitol, 
Microcrystalline cellulose, Talc and Magnesium stearate. The tablets were 
evaluated for physical properties including Hardness, Weight variation, 
Thickness, Friability, Drug content, Wetting time, Water absorption ratio, In-
vitro disintegration time, In-vitro dissolution study and also Drug release 
kinetic study. The Hardness, Weight variation, Thickness, Friability and Drug 
content of tablets were found to be acceptable according to pharmacopoeial 
limits. An optimized tablet formulation was found, which provided short wetting 
time of 45 sec, water absorption ratio of 55 and In-vitro disintegration time of 
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98 sec. because of the amount of superdisintegrant i.e. crospovidone was 
significantly affected the dependent variables like wetting time, Water 
absorption ratio and In-vitro disintegration time. The best in-vitro drug release 
was found to be in optimized formulation i.e.99.88% during the end of 12 min. 
The in-vitro drug release data of all Perindopril sublingual tablets were 
subjected to goodness of fit test by linear regression analysis according to 
Zero order equation, first order equation, Higuchi’s equation and Krosmeyer-
Peppas equation to ascertain the mechanism of drug release. 
Mohd Abdul Hadi et al (2017)  developed sublingual administration of 
felodipine (antihypertensive drug) offer suitable and practical approach in 
serving the desired objective of faster disintegration and dissolution 
characteristic with increase bioavailability and to know the effects of two 
synthetic superdisintegrants  like crospovidone and sodium starch glycollate 
was done by taking different ratios. Prepared tablets were subjected to 
different evaluation parameters such as hardness, thickness, friability, weight 
variation, and drug content uniformity, in vitro disintegration time, wetting time, 
in vitro dissolution studies and stability studies are carried out by using best 
formulation. Thus, sublingual tablet of Felodipine could be an alternative route 
to avoid gastrointestinal side effect as well as bypass hepatic first pass 
metabolism. The formulated sublingual tablets may act as a potential alternate 
for the Felodipine oral tablet. 
Syed Suhaib Ahemed et al (2017) developed fast dissolving 
sublingual tablets of gabapendin using superdisintegrants like 
crosscarmellose sodium, crosspovidone, sodium starch glycolate, PVP-K30. 
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All formulations were evaluated post compression parameters like hardness, 
friability, drug content uniformity, dissolution test and disintegration test. 
Pawar P P  et al (2016)  developed sublingual tablets  of ondansetron 
HCL is selective inhibiter of type 3 serotonin (5HT3) receptor & shows 
antiemetic action.  it is easier route of administration, it is also used in patients 
of dysphasia (difficulty in swallowing). In the present study the research was 
done for the replacement of superdisintegrants that are Cross carmalose 
sodium & Sodium starch glycolate. The formulations were evaluated for 
preformulation & post-formulation studies. The disintegration time was within 
the range of 12 – 19 seconds & the results were satisfactory. 
Somya Sah et al. (2016) Oral administration is one of the most 
convenient forms for the intake of drug due to ease of administration, 
painless, versatility, and paramount patient compliance. The demand of fast 
disintegrating tablets has been growing, during the last decades especially for 
geriatric and pediatric patients due to dysphasia. So the new drug delivery 
known as orally disintegrating tablets came to existence. As nowadays most 
of the people need effective relief within a short period of time so sublingual is 
the most suitable form of administration. These tablets disintegrate and 
dissolve rapidly in saliva due to interaction with our salivary enzymes. 
Shailesh T Prajapath et al (2016) formulated sublingual tabets of 
zolmitriptan. It  is a 5-HT receptor agonist (1B/1D) used in the acute treatment 
of migraine having low bioavailability about 40% orally due to hepatic first 
pass metabolism. Sublingual tablets were prepared using ispaghula husk 
powder, gellan gum, sodium alginate as super disintegrating polymers and 
citric acid, tartaric acid and camphor as permeation enhancers by direct 
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compressible technique and evaluated for weight variation, thickness, 
friability, content uniformity, hardness, disintegration time, wetting time, in-
vitro drug release, in-vitro and ex-vivo permeation study. The in-vitro 
disintegration time of the optimized formulation was 9 ± 2 sec and all 
formulations showed 100% of dissolution within 6 ± 2 min. Formulation 
containing 4% of gellan gum  showed highest disintegration and 2% of citric 
acid formulation  showed highest permeation 88% within 30 min and ex-vivo 
permeation was 52% within 30 min. From this the sublingual tablet formulation 
gives better results using natural super disintegrant for fast onset of action. 
Shailesh T Prajapati et al (2016) prepared sublingual tablets of 
sumatriptan succinate is a selective 5-hydroxytryptamine-1 receptor agonist 
effective in the acute treatment of migraine headaches, having low 
bioavailability of about 15% orally due to first-pass metabolism. The intensely 
bitter taste of Sumatriptan succinate was masked and to formulated fast-
acting, taste-masked sublingual tablet formulation by solid dispersion method 
with mannitol and ion exchange with Kyron T 114 because it releases the 
drug in salivary pH. For a better feel in the mouth, menthol and sweetener Na 
saccharine were added to the tablet formulation. The tablets were prepared 
by direct compression and evaluated for weight variation, thickness, friability, 
drug content, hardness, disintegration time, wetting time, in vitro drug release, 
and in vitro permeation study. Optimized batches disintegrated in vitro within 
28-34 s. Maximum drug release could be achieved with in 10 min for the solid 
dispersion batches and 14-15 min for the ion-exchange batches with Kyron T 
114. The optimized tablet formulation showed better taste and the formulated 
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sublingual tablets may act as a potential alternate for the Sumatriptan 
succinate oral tablet. 
Ahmed E Aboutlab et al (2016) formulated sublingual tablets of 
domperidone (DMP), anti emetic drug having a poor oral bioavailability (13-
17%) due to extensive first pass metabolism. The solubility enhanced by solid 
dispersions of DMP with Pluronic F-68 were prepared in different weight ratios 
by fusion method and they were evaluated for their in vitro dissolution rate to 
select the best ratio for final formulation. Then, solid dispersions were 
formulated into sublingual tablets in combination with various soluble 
excipients. Sublingual tablets were prepared by direct compression technique 
and evaluated for their physical properties, in vitro dissolution rate and 
kinetics of drug release. The best formulae were selected for in vivo studies in 
rabbits in comparison with marketed oral tablets; Motinorm ®. Solid 
dispersions of DMP with Pluronic F-68 in a weight ratio of 1:7 (w/w) showed 
the highest dissolution rate and were selected for sublingual tablets 
formulation. Sublingual tablets formulae S16 (containing Fructose and 10% 
w/w Ac-Di-Sol) and S20 (containing Fructose and 10% w/w Explotab) showed 
the best results and were selected for in vivo studies in rabbits. The selected 
formulae showed marked enhancement of DMP bioavailability compared with 
the commercial oral tablets; Motinorm ® , with relative bioavailability values of 
432.49±10.13% and 409.32±11.59 % for S16 and S20, respectively. From the 
results confirmed that sublingual tablets were an effective tool for DMP 
delivery with marked enhancement of bioavailability. 
Sardarmal Yadav et al (2015) developed sublingual tablets of ramipril 
are most effective against hypertension and provide rapid onset of action with 
CHAPTER III                                                                  LITERATURE REVIEW 
Dept of Pharmaceutics, College of Pharmacy, MMC, Madurai-20 Page 45 
 
rapid drug release. The sublingual tablets of ramipril avoid first pass effect so 
that provide complete utilization of drug and it provide maximum drug release 
(98.01%). 
Baljinder Singh et al (2015) developed sublingual tablets of 
telmisartan to improve the solubility and bioavailability by encapsulating it 
inside the cavity of β-cyclodextrin. Sublingual tablets using polymers like CP 
and SSG and CCS by employing direct compression method and the 
prepared tablets were evaluated for thickness, uniformity of weight, hardness, 
friability within the IP limits. Out of 6 formulations, the tablets which contain 
5% of CP had shown low wetting time 30.26, low in vitro disintegration time 
26.08 sec, high water absorption ratio 95.66% and highest drug release 
profile i.e 80.33% which release the drug within the 3 minutes. 
Mohmed Akbar et al (2015) prepared sublingual tablets of doxofylline 
using super disintegrant like sodium starch glycolate and crosscarmellose 
sodium with aview to obtain rapid disintegration when held beneath the 
tongue, permitting direct absorption of active ingredient by the oral mucosa 
and it also by passes first pass metabolism and improve the bioavailability. In-
vitro release kinetic studies were carried out for zero order, first order, and 
Higuchi kinetic model. FTIR studies were carried out for pure drug doxofylline, 
MCC, PVPK30, SSG, crosscarmellose and optimized formulation to confirm 
that there is no interaction between drug and different excipients.DSC studies 
carried out to know the thermal stabilities of drug and optimized formulation. 
Prathusha B et al (2015)   developed and optimized sublingual tablets 
of Nifedipine for the treatment of angina and hypertension. The solubility of 
Nifedipine was improved by solid dispersion and FTIR studies confirmed the 
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absence of drug-excipients interactions. Sublingual tablets were prepared by 
direct compression method using various concentrations of superdisintegrant 
and diluents. The formulated tablets were evaluated for hardness, thickness, 
weight variation, friability, wetting time, in-vitro dispersion time, water 
absorption ratio, drug content, disintegration time and the results were within 
USP limits. The optimized formulation showed shorter wetting time 22 sec, 
invitro dispersion time of 41 sec and disintegration time 1 min 45 sec and 
showed 88 folds increase in solubility and in vitro-dissolution at 10 min 
compared to pure Nifedipine and 10 fold increase compared to marketed oral 
Nifedipine tablets. The drug releases from the sublingual tablets follow 
Higuchi release kinetics and diffusion was the main mechanism for drug 
release. 
Narendra Yadav et al (2015) prepared sublingual tablets of terbutaline 
sulphate is a selective B2 bronchodilator which is used in the treatment of 
asthma. The conventional terbutaline sulphate tablets available in the market 
are not suitable for onset of action where quicker onset of action required. The   
tablets were prepared by using mannitol, microcrystalline cellulose pH102 
(F1) and lactose monohydrate, microcrystalline cellulose pH102 (F4) as filler 
and its combination in different ratio, Crospovidone as superdisintegrant and 
sodium lauryl Sulphate as permeability enhancers by drug dispersion direct 
compression method. The formulation F1 found the 93.51% of % drug 
permeability, 8 seconds disintegration time and 96.95% drug release within 
one minute. The formulation F4 also found the 98.25% of drug permeability, 
13 seconds disintegration time and 90.31% drug release within one minute. It 
was concluded that the sublingual tablet of Terbutaline  sulphate can be 
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formulated for sublingual absorption of drug in emergency treatment of 
asthma by direct compression drug dispersion method. 
Dipti Maheswari S and Pankaj H et al (2014) developed fast 
disintegrating sublingual tablets by solubility enhancement as Lercanidipine 
HCL undergoes first pass metabolism in liver and gut wall and it offers a fast 
relieve from angina pain and hypertension. For solubility enhancement 
screening of different polymers like povidone k-30, PEG-6000, poloxamer and 
HPMC3 were done using phase solubility study and Povidone k-30 was 
selected and solubility increased by solid dispersion by spray drying method 
was selected. Aspartame and mannitol were used as a sweetener. The 
preformulation studies showed no interaction between drug and polymer or 
with other additives. The optimized formulation containing Drug : Polymer 
ratio (1:3) and crosspovidone 5% showed grater dissolution (more than 95% 
within 20 min), satisfactory in vitro disintegration time (37 sec). 
Kundan P Chaudhari et al (2014) prepared fast disintegrating 
sublingual tablets of amlodipine besylate by using different disintegrant for the 
potential emergency treatment of angina and hypertension. The sublingual 
tablets were prepared by direct compression using Tulsion-671 and 
crospovidone as a superdisintegrants. The prepared batches of sublingual 
tablets were evaluated for hardness, friability, drug content uniformity, wetting 
time, water absorption ratio, and in-vitro disintegration time. All prepared 
tablets shows the disintegration time less than 1 minute which was within the 
Pharmacopoeial limit. From the results revealed that the tablets had 
acceptable hardness 3.15 – 3.59 kg/cm2 and disintegration time 11 – 59 
seconds. Optimum formulation of Tulsion-671 and crosspovidone  in 
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combination showed disintegration time of 11 seconds and 95.89 % of drug 
release. 
Balusu Haarika et al (2014) prepared fast disintegrating rizatriptan 
benzoate sublingual tablets for the treatment of migraine. The sublingual 
tablets were prepared by direct compression method using the 
superdisintegrants like sodium starch glycolate, croscarmellose sodium, cros 
povidone. The powder properties of all formulations were evaluated for 
diameter, thickness, weight variation, hardness, friability, wetting time, water 
absorption ratio, drug content, in-vitro and in-vivo disintegration time as well 
as in-vitro release. The optimized formulation was characterized by scanning 
electron microscopy (SEM), differential scanning calorimetry (DSC), powder 
x-ray diffraction (PXRD), and fourier transform infrared spectroscopy (FTIR). 
The optimized formulation containing crospovidone disintegrated very fast and 
very in-vitro drug release was very high. 
Sheeba F R et al (2014) developed fast disintegrating sublingual 
tablets of nifedipine for the potential emergency for treatment of angina and 
hypertension. Nifedipine undergoes first pass metabolism in liver and gut wall 
which has oral bioavailability of 43-77%. But the sublingual tablets of 
nifedipine bypasses the metabolism and offers fast relieve from pain and 
hypertension. The tablets are prepared by direct compression using 
superdisintegrant like cros carmellose sodium, sodium sararch glycolate, cros 
povidone. The studied sublingual tablet group V shows a lesser T50% 
compared to conventional oral tablet. The group V also indicates the fast 
dissolution and disintegration rate of the optimized nifedipine sublingual tablet, 
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which is prerequisite for rapid management of angina and hypertension 
disease. 
Brahmdutta raval et al (2014) prepared sublingual tablets ivabradine 
hydrochloride for reduction in ischemic condition in Stable Angina. Efficacy of 
sublingual administration, higher permeability of drug and improvement in 
bioavailability achievement for drug were the factors that lead to the 
development of the present work. Compatibility studies of drug and polymer 
were performed by FTIR and demonstrated no interaction between drug and 
excipients. Tablets were prepared by direct compression using different 
concentration of Croscarmellose sodium and Crospovidone. Pre-compression 
parameters for blend were in the range. Prepared tablets were evaluated for 
disintegration time, wetting time, Water absorption ratio, %CDR and Ex-vivo 
permeability study. Formulation F6 (3% CCS, 4.5% CP) was found to be the 
optimized and showed disintegration time of 25 sec. In vitro drug release was 
found within 7 minutes and maximum relative permeability from F6 was up to 
21 minutes. 
Brahmbhatt et al (2014) prepared sublingual tablets of Naratriptan 
used for the treatment of migraine and for pre and post Compression 
parameters was undertaken. The tablets were prepared by direct 
compression method using super disintegrates. After selection of 
superdisintegrants tablets were prepared by using polymer for reducing the 
flushing action of saliva and provide enough time for drug absorbed. The 
prepared tablets were evaluated for their physical and chemical property. The 
permeation study was performed on Goat mucosa for optimized batch. No 
interactions were found between drug and excipients. Formulation containing 
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Crosspovidone shows immediate drug release. Formulation containing 
Chitoson shows fast drug release as compared to superdisintegrants alone. 
Sublingual tablets were prepared by direct compression method using 
Crosspovidone as a superdisintegrants. But it is more effective in combination 
with Chitoson. As a result, sublingual tablet administration of Naratriptan 
formulated with appropriate excipients and especially with Chitoson seems 
promising alternative to traditional routes. 
Jaleh Varshosaz et al (2014)  prepared mucoadhesive sublingual 
tablets of Lorazepam, a benzodiazepine drug is used as an antianxiety, 
sedative, hypnotic, and anticonvulsant drug may accelerate the onset of its 
action. To optimize the formulation of the mucoadhesive sublingual tablets of 
lorazepam seven variables including: disintegrating agent type (Primojel or 
Kollidone), filler [Silicified microcrystalline cellulose (SMCC) or Avicel PH 101], 
carrier powder (mannitol or lactose), disintegrating agent content (5 or 10%), 
lubricant type (Mg-stearate or Aerosil), drug content (1 or 2 mg) and mixing 
time (12 or 24 h) were studied by the Taghuchi design and nine different 
formulations were prepared. The tablets were tested for their thickness, 
hardness, weight variation, drug content uniformity, assay, porosity, 
disintegration time, bioadhesion tensile strength and dissolution efficiency and 
the effect of different studied formulation parameters were studied on their 
properties. The formulation of tablets was optimized considering their 
dissolution efficiency within 10 minutes (DE10%). The optimum formulation 
obtained from 2 mg of the drug, 1.2 mg Mg-stearate, 6 mg of Primojel, 20.8 
mg of Avicel, 90 mg of mannitol which was mixed for 12 hours with the drug. 
This tablet with the DE10% of 81.30±2.50%, bioadhesion of 34.15±0.15%, 
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and disintegration time of about 14 sec seems promising as a rapid 
disintegrating and mucoadhesive sublingual tablet for lorazepam. 
Tejas B Parmar et al (2014) developed sublingual tablets of valsartan 
to overcome first pass metabolism and provide rapid onset of action. The solid 
dispersion of valsartan prepared with different carriers like β-cyclodextrin, 
poloxamer 407, PEG 6000, PEG 4000, poloxamer 188, pvp k-30. The 
proportion of drug and carrier was selected 1:1 due to dose limitation of drug 
and solubility study was performed to select the carrier, for β-cyclodextrin 
molar ratio(1:1) was selected. The tablets were prepared by direct 
compression method using different superdisintegrants like sodium starch 
glycolate, cross carmellose sodium, cross povidone. The formulation 
containing Drug-Beta cyclodextrin complex(1:1) and cross carmellose 
sodium(5%) showed greater drug dissolution and disintegration time(19 sec). 
Karan kumar M et al (2014) developed  sublingual tablets of 
Terazosin Hydrochloride, which is an effective drug in the treatment of Benign 
Prostate Hyperplasia, Hypertension. Sublingual tablets were prepared by 
direct compression method using different superdisintegrating agents such as 
Crosspovidone, Sodium starch glycolate and Crosscarmellose sodium. The 
tablets were evaluated for precompression studies like Bulk density, Tapped 
density, Carr’s index, Hausner’s ratio and post-compression studies like 
Thickness, Hardness, Weight variation, Friability, drug content, Wetting time, 
Water absorption ratio, in-vitro disintegration time, in-vitro dispersion time, in-
vitro dissolution study and also drug release kinetic study. An optimized 
formulation i.e. F6 was found, which provided short wetting time of 67sec, 
water absorption ratio of 39.01 , in-vitro disintegration time of 61sec and in-
CHAPTER III                                                                  LITERATURE REVIEW 
Dept of Pharmaceutics, College of Pharmacy, MMC, Madurai-20 Page 52 
 
vitro dispersion time of 112sec. From the above results It indicated that the 
amount of superdisintegrant i.e. Crosspovidone was significantly affected the 
dependent variables like Wetting time, Water absorption ratio, in-vitro 
disintegration time and in-vitro dispersion time and the best in-vitro drug 
release in formulation F6 i.e. 102% during the end of 15min. 
Balkrishna Prajapati et al (2014) developed mouth dissolving 
sublingual tablets of cimetidine to treat abdominal crampsby direct 
compression method using superdisintegrants like sodium starch glycolate, 
cross caarmellose sodium, cross povidone. Binders like PVP, MCC were 
used. The FT-IR study conducted for the no compatibility between drug and 
polymers. Th e tablet thickness ranged between 4.066-5.166 mm, hardness 
ranged between 3.04 - 4.2 kg/cm2, friability ranged between 0.194-.302, the 
drug content was found be range of 96.02-99.54%. The stability study for 
three months at 40±200 C, 75±2% RH and results showed that the formulation 
was found to be stable. 
Ajeet M Godbole et al (2014) developed sublingual tablets of 
ondansetran hydrochloride by direct compression method using different 
superdisintegrants like cros povidone, sodium starch glycolate and Ac-Di-Sol. 
The tablets contain ratio of mannitol : maltose : corn starch like 19:2:1 gave 
better tableting performace with respect to pre-compression and post-
compression parameters. Formulation contain 4% cros povidone and PVP K-
30 in ratio of 0.5% showed uniform release of drug over a period of 20 
minutes with complete solubilization of tablet compared to that of gelatin and 
carbopol 934. 
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Aparna B et al (2014)   prepared sublingual tablets of  aripiprazole. It 
is an antipsychotic drug used for the treatment of schizophrenia. The 
sublingual tablets were prepared by direct compression method by using 
various ingredients such as Crospovidone, Crosscarmellose sodium, Sodium 
starch glycolate, Microcrystalline cellulose, Aspartame, Aerosil and 
Magnesium stearate. Fourier transform infrared spectroscopy was confirmed 
the absence of any drug- polymer interactions. Twelve formulations (F1-F12) 
of sublingual tablets were prepared by using the various concentrations of 
super disintegrate. The formulated tablets were evaluated for thickness, 
hardness, weight variation, friability, wetting time, water absorption ratio, 
disintegration time, drug content and in-vitro drug release studies. The 
optimized formulation was found, which provided short wetting time of 25 sec, 
water absorption ratio of 65 sec and disintegration time of 27 sec. The best in- 
vitro drug release was found to be 97.17% at the end of 14 minutes. 
Jay G Bhimani et al (2014) developed sublingual tablets of ropinirole 
is rapidly absorbed in humans and the  tablets were prepared by direct 
compression procedure using different concentration of Crosspovidone and 
Crosscarmellose Sodium. Preformulation property of API was evaluated. 
Post-compression parameters such disintegration time, wetting time, water 
absorption ratio in vitro drug release and ex vivo permeability study of 
optimized formulation were determined. FTIR spectroscopy study revealed 
that there was no possible interaction between drug and polymers. The 
disintegration time of optimized formulation was up to 40 sec. The in vitro 
release of Ropinirole hydrochloride was up to 9 minutes. The percentage 
relative permeability of Ropinirole hydrochloride from optimized sublingual 
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tablets was found to be 90.51% after 30 minutes. Sublingual tablets 
Ropinirole hydrochloride of were successfully prepared with improved 
bioavailability. 
Ruchita Jaiswani et al. (2014) Oral mucosal drug delivery via mucous 
membrane is considered to be a promising alternative to the oral route. 
Sublingual route is a useful gives rapid onset of action is desired with better 
patient compliance than orally ingested tablets. In terms of permeability, the 
sublingual area of the oral cavity (i.e. the floor of the mouth) is more 
permeable than the buccal (cheek) area, which in turn is more permeable 
than the palatal (roof of the mouth) area. The portion of drug absorbed 
through the sublingual blood vessels bypasses the hepatic first‐pass 
metabolic process. Sublingual technology for patients need enhanced 
lifecycle management to convenient dosing for geriatric, pediatric and patient 
with dysphagia. This review highlights the sublingual dosage forms for the 
treatment of migraine, factors affecting the sublingual absorption, advantages, 
various in vitro and in vivo evaluation parameters and commercially available 
sublingual dosage forms. 
Mujtaba Ali et al (2013) prepared sublingual tablets, containing the 
antiemetic drug ondansetron hydrochloride (OH) which suffers an extensive 
first-pass effect. OH is a bitter drug its taste was masked by complexing with 
Tulsion 335 using precipitation technique and formulations were prepared by 
direct compression method using a bioadhesive polymer. The optimized tablet 
formulation, containing OH- 5 mg (equivalent to 10.2 mg of DRC), Mannitol-
71.8 mg, SMCC-11.5 mg, Cross-linked PVP-6 mg and Magnesium stearate-
0.5 mg which gave a short DT of 23.45 ± 3.14 sec, maximum drug release 
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91.33 ± 3.11% and permeation through porcine sublingual mucosa 63.23 ± 
2.01%. From the results, the inclusion of Cross-linked PVP, a bioadhesive 
polymer, in sublingual tablet formulations, prevented ondansetron from being 
swallowed, without hindering its release and absorption.  
Trambadia, Dipen A et al (2013) developed sublingual tablets of 
metoprolol succinate is a potent cardio selective beta-1 adrenoreceptor 
blocker, mostly used in the treatment of acute disorders such as angina 
pectoris and hypertension. The main objectives of fast disintegrating 
sublingual tablet the comparative study between cross carmellose sodium and 
sodium starch glycolate was performed. The fast disintegrating sublingual 
tablets were prepared by different concentration of super disintegranting 
agents such as sodium starch glycolate (2%, 4%, 5%, and 6%) and cross 
carmellose sodium (2%, 4%, 5%, and 6%) by direct compression technique. 
The disintegration time of optimized formulation was up to 24 sec and in vitro 
drug release of Metoprolol succinate was up to 3 minutes. The optimized 
formulation containing 5% cross carmellose sodium which gives better 
swelling and wicking properties offers effective drug dissolution. 
Shafayad Hossain Md et al. (2013) develop a formulation of 
Ticagrelor 90 mg tablets that is equivalent to the reference product using 
similar excipients to match the in-vitro dissolution profile. A compressed 
coated tablet was formulated consisting of Ticagrelor and excipients 
conforming to the USP/BP monograph and below maximum amount allowed 
per unit dose. The physical characteristics of powder blends were evaluated. 
The compressed core and coated tablets were evaluated for thickness, 
hardness, weight variation, friability, disintegration, dissolution, drug content 
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and stability. The powder blends for all formulations showed satisfactory bulk 
density, tapped density, compressibility index, hausner ratio, angle of repose 
and moisture content. All the core and coated tablets showed acceptable 
pharmaco-technical properties in terms of thickness, hardness, weight 
variation, friability, disintegration. Dissolution performances were varied 
depending on the composition of matrix tablet. Finally a formulation batch B05 
consisting of Ticagrelor (34.61%), mannitol (61.15%), sodium starch glycolate 
(2.69%), hypromellose (HPMC-2910, 5cps) (0.77%), purified talc (0.38%), 
magnesium stearate (0.38%) and opadry grey (21k57558) (2%) showed 
maximum similarity with the reference product. Using this formulation a 
pharmaceutical will be able to meet regulatory compliance. 
Naimish A et al. (2013) Schizophrenia and schizoaffective disorder 
are severe and chronic psychiatric illnesses for which treatment compliance is 
important in the prevention of relapse. Atypical antipsychotic drugs, such as 
risperidone, have been found to be effective in the treatment of a range of 
psychiatric disorders. Sublingual tablet of oral formulations of these drugs 
have been developed to improve their acceptability to patients and thus 
improve compliance. Improve solubility, bioavailability and to achieved rapid 
onset action was focus of present investigation.  
Sundarshan K Singh et al (2012) formulated sublingual tablets of 
Lisinopril is the drug of choice in hypertension and have bioavailability of the 
drug is 25% of orally administered dose. The Objective of present study is to 
develop the sublingual tablet of Lisinopril and improve its bioavailability, in 
view to maximize therapeutic effect of the drug. The directly compressed 
tablet of Lisinopril was formulated using Mannitol, Micro Crystalline Cellulose 
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and Kyron T-314 as super disintegrant. Formulation (F1-F7) was evaluated for 
disintegration time and in vitro release study. Further the optimized sublingual 
formulation (F6) and marketed formulation was subjected to in-vivo 
comparative bioavailability study using white New Zealand rabbits. It was 
observed that concentration of Micro Crystalline Cellulose, Kyron T-314 has 
significant effect on the disintegration time of Lisinopril sublingual tablet 
formulations. The super disintegrant concentration 5% w/w (Kyron T-314) was 
found optimum in all tablet formulations. The bioavailability of optimized 
sublingual tablet of Lisinopril was improved by 1.44 times as compared to 
conventional oral marketed tablet of Lisinopril. The administration of 
sublingual tablet becoming easy and it will improve patient compliance to 
therapy for hypertension for pediatrics, geriatric and bed ridden patient 
Nikunj J Aghera et al (2012) Sublingual tablets of Losartan Potassium 
were prepared to improve it’s to avoid pre-systemic metabolism in the 
gastrointestinal tract and hepatic first pass elimination. The Sublingual tablets 
were prepared by direct compression procedure by using different 
concentration of starch 1500 and microcrystalline cellulose. Compatibility 
study between drug and polymer were performed by FTIR specroscopy and 
DSC. Preformulation study of API was evaluated. Postcompressional 
parameters such as disintegration time, wetting time, water absorption ratio, 
invitro drug release and invivo bioavailability of optimized formulation were 
determined. The disintegration time for optimized formulation was up to 48 
sec and invitro drug release of losartan potassium was 15 min. the 
percentage relative bioavailability of Losartan Potassium from optimized 
sublingual tablets was found to be 144.7 %. 
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Kharshoum RM et al (2012)  prepared a novel fast disintegrating 
Bisoprolol Hemifumarate (BH) tablet formulation for sublingual administration 
based on the use of 2- hydroxypropyl-βcyclodextrin (HP-βCD) which forms an 
inclusion complex with (BH) to improve the permeability of the drug to 
sublingual membrane, in addition to mask the taste of the drug through the 
inclusion complex (BH) using superdistintegrants like crosscarmellose sodium 
and crospovidone in concentration of (5%) and tablet  were prepared by direct 
compression method using different mucoadhesive polymers such as 
chitosan and polyethylene glycol 6000 at different concentration (3% and 6%) 
for reduction the flushing action of saliva and to provide enough contact time 
for drug to be absorbed. The tablets were evaluated for the weight variation, 
hardness, friability, wetting time, disintegration time and dissolution study. The 
formulae B2 and B7 possessed the lowest disintegration time due to the 
presence of the high concentration of chitosan, which has some disintegration 
action, thus were subjected to a pharmacokinetic study using human 
volunteers. The bioavailability of B2 was significantly higher than that of the 
reference (Concor®) (p > 0.05). Thus, the present investigations suggest that 
(BH) sublingual tablets allowed the rapid tablet disintegration, improved 
bioavailability and effective in emergency treatment of anginal pain and 
hypertension. 
Kharshoum RM et al (2011) formulated Ketotifen fumarate fast 
disintegrating sublingual tablets offers a fast relieve of asthma. To achieve 
this goal, superdisintegrants and diluents were evaluated for their effect on 
the disintegration behavior of KF tablets. Full factorial design (24) was applied 
for a screening study in which four factors were used at two levels (low and 
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high). The four factors, were the type of disintegrants either Ac-di-sol or 
Explotab, the concentration of each disintegrant (either 3% or 5% w/w), the 
binder either Avicel PH101 or PEG6000 and finally the diluent was either 
spray dried lactose or granular mannitol. Hydroxy propyle betacyclodextrin (2-
HP-CD) was used for increasing the absorption of KF tablets formulae. Solid 
binary system of KF with betacyclodextrin (2-HP-CD) was prepared in molar 
ratios of 1:1 of drug to cyclodextrin. The formulation containing Ac-di-
sol(5%w/w) , Avicel PH101(10%w/w) and granular mannitol as diluent was 
selected as best formulation that has the least disintegration time of 20 
seconds and the highest cumulative dissolution percent of 80.28% after the 
first minute. 
Bayrak Z et al (2011) prepared sublingual tablets of zolmitriptan for the 
treatment of migraine and the tablets were prepared by direct compression 
method using different mucoadhesive polymers such as hydroxypropyl methyl 
cellulose, chitosan and sodium carboxy methyl cellulose at a concentration 
range of 0.5-5% to reduce flushing action of saliva and provide enough time 
for drug to be absorbed. It was also concluded that microcrystalline cellulose, 
spray-dried lactose and sodium starch glycolate are the appropriate excipient 
and formulated in good proportions. In vivo studies indicated that formulation 
containing 5% chitosan has the maximum C(max) and AUC and minimum 
t(max) values (p<0.05) and sublingual tablet administration of zolmitriptan 
formulated with appropriate excipients and especially with chitosan seems 
promising alternative to traditional routes. 
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Sindu Abraham et al (2010) developed sublingual tablets of 
rabeprazole sodium, a class of proto pump inhibitors which is effective in the 
treatment of acid peptic disorders. The tablets were prepared by wet 
granulation method using superdisintegrats like cros povidone and cross 
carmellose sodium. An optimized formulation was prepared which provided a 
short wetting time of 27 seconds and in-vitro dispersion time of 32 seconds.  
Rajat Sharma et al (2010) prepared fast dissolving sublingual tablet of 
glipizide for potential emergency treatment for diabetic coma. The 
superdisintegrant used in this study was crospovidone. The tablets were 
evaluated for weight variation, hardness, friability, wetting time, water 
absorption ratio, and disintegration time and dissolution study. The tablets 
were prepared by wet granulation procedure. Sublimation of naphthalene from 
tablets resulted in better tablets as compared to the tablets prepared from 
granules that were exposing to vacuum. The systematic formulation approach 
helped in understanding the effect of formulation processing variables. 
Saadia A Tayel et al (2010) prepared sublingual tablets, containing the 
antiasthmatic drug ketotifen fumarate which suffers an extensive first-pass 
effect, using the fast-melt granulation technique. The powder mixtures 
containing the drug were agglomerated using a blend of polyethylene glycol 
400 and 6000 as meltable hydrophilic binders. Granular mannitol or granular 
mannitol/sucrose mixture were used as fillers. A mechanical mixer was used 
to prepare the granules at 40°C. The method involved no water or organic 
solvents, which are used in conventional granulation, and hence no drying 
step was included, which saved time. Twelve formulations were prepared and 
characterized using official and non-official tests. Three formulations showed 
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the best results and were subjected to an ex vivo permeation study using 
excised chicken cheek pouches. The optimized formulation possessed the 
highest permeation coefficient due to the presence of the permeation 
enhancer (polyethylene glycol) in an amount which allowed maximum drug 
permeation, and was subjected to a pharmacokinetic study using rabbits as 
an animal model. Thus, fast-melt granulation allowed for rapid tablet 
disintegration and an enhanced permeation of the drug through the sublingual 
mucosa, resulting in increased bioavailabililty. 
Sindhu Abraham et al. (2010) developed sublingual tablets of 
Rabeprazole Sodium, a class of Proton pump inhibitors which is effective in 
the treatment of acid peptic disorders. The tablets were prepared by wet 
granulation method based on a central composite design. The formulation 
variables included quantity of Crospovidone, (X1), and quantity of 
Croscarmellose Sodium (CCS), (X2), while the response variables determined 
were wetting time and In vitro dispersion time. A quadratic model was used to 
quantitatively evaluate the main effects and interaction. Surface response 
plots are presented, to graphically represent the effect of the independent 
variables on the wetting time and disintegration time. The hardness of all the 
formulations was in the range 3.0 – 4.0 kg/cm2. 
Kazerani H et al. (2009) This study aimed to evaluate the response 
rate, clinical efficacy and onset of action of sublingual captopril in patients 
diagnosed with hypertensive urgency. In this cross-sectional study (67 female 
and 34 male) patients with a diagnosis of hypertensive urgency (systolic 
pressure greater than or equal to 180 mmHg and/or diastolic pressure greater 
than or equal to 110 mmHg, and no findings of target organ damage) was 
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included. and blood pressure was measured during a follow-up period of 120 
minutes. The Sublingual captopril (25 mg) was administered and blood 
pressure was measured during a follow-up period of 120 minutes, Sublingual 
captopril can be used as an successful, simply applicable and safe treatment 
and management of hypertensive need for 120 minutes for those who do not 
get multidrug antihypertensive regimens. 
Noushin Bolourtchin et al (2008) developed sublingual tablets of 
captopril which is an effective drug in the treatment of hypertension. The 
tablets were prepared by direct compression method using different 
ingredients such as PVP, starch 1500, sodium starch glycolate. Tablets were 
evaluated for the physical properties including hardness, friability, wetting 
time, water absorption ratio, disintegration time and dissolution time. 
David harries et al. (1992) The delivery of drugs via the mucous 
membranes lining the oral cavity with consideration of both systemic delivery 
and local therapy ,the structure and composition of mucousa at different site 
in the oral cavity, factor affecting mucosal permeability, penetration 
enhancement, selection of appropriate experimental systems for studying 
mucosal permeability ,and formulation factor relevant to the design of systems 
for oral mucosal delivery are discussed. The sublingual delivery gives raped 
absorption and good permeability this system is not suitable for sustained 
delivery systems. For this reason buccal mucosa is good for number of 
peptide drugs. It mainly low molecular weight, high potency. it is safe route for 
penetration enhancement and to delivery in systemic circulation. 
 
CHAPTER III                                                                  LITERATURE REVIEW 
Dept of Pharmaceutics, College of Pharmacy, MMC, Madurai-20 Page 63 
 
John DN et al. (1992) The pharmacokinetics and pharmacodynamics 
of verapamil administered via the oral and sublingual routes were compared 
in a randomized, two way cross-over study involving six healthy male 
volunteers. Administered sublingually, a verapamil 40 mg crushed tablet 
produced a significantly higher peak plasma concentration, a greater rate of 
absorption, and greater bioavailability when compared with orally 
administered verapamil. In comparison with oral dosing, PR intervals were 
significantly (P less than 0.05) prolonged between 30 and 90 min after 
sublingual verapamil dosing. Correlations between log plasma verapamil 
concentration and percentage increase in PR interval were greater after 
sublingual compared with oral dosing in all volunteers. 
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AIM OF WORK 
 
Difficulty in swallowing (dysphagia) is a common problem of all age 
groups, especially the elderly and pediatrics, because of physiological 
changes associated with these groups. Other categories that experience 
problems using conventional oral dosage forms include are the mentally ill, 
uncooperative and nauseated patients, those with condition of motion 
sickness, sudden episodes of allergic attack or coughing. 
Sometimes it may be difficult to swallow conventional products due to 
unavailability of water. These problems led to the development of a novel type 
of solid dosage form called sublingual tablets, which disintegrate and dissolve 
rapidly in saliva without the need of drinking water. Upon ingestion, the saliva 
serves to rapidly dissolve the dosage form.  
The saliva containing the dissolved or dispersed medicament is then 
swallowed and the drug is absorbed in the normal way. Some drugs are 
absorbed from the mouth, pharynx, and oesophagus as the saliva passes 
down into the stomach. In these cases, the bioavailability of drugs is 
significantly greater than those observed from conventional dosage forms.    
So, the sublingual drug delivery systems have been introduced to 
overcome the drawback of low bioavailability problems associated with 
conventional oral dosage forms. Therapeutically active molecules for the 
treatment and prevention of new and existing diseases are currently being 
developed. Although pharmacological activity is the primary requirement for a 
molecule to be used as a therapeutic agent, it is equally important that the 
molecule reaches its site of action, and hence drug delivery technologies have 
assumed importance. Nevertheless, many existing and new molecules 
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provide challenges of poor pharmacokinetics leading to low bioavailability. 
Drug delivery systems such as sublingual dosage forms are used to 
overcome these challenges. Although the cost of these drug delivery 
technologies is considerably low and substantially less than the cost of 
developing a new molecule. Hence, a continued interest exists in developing 
novel drug delivery systems for the delivery of active agents. In Acute 
Coronary Syndrome there is increase in blood pressure which may lead to 
sudden heart attack. Ticagrelor is the drug of choice in Acute Coronary 
Syndrome.  
Oral administration of Ticagrelor is associated with bioavailability 
problem. Bioavailability of the drug is 36% of orally administered dose. 
Mucosa of a sublingual cavity is relatively permeable with rich blood supply, 
also sublingual drug delivery avoids pre systemic elimination of drug in GI 
Tract make this portal of drug administration quite attractive and feasible site 
for systemic delivery of drugs. So, the aim of present work was to develop and 
characterize sublingual tablet of Ticagrelor with improved bioavailability. 
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PLAN OF WORK 
 
I. PREPARATION OF STANDARD CALIBRATION CURVE 
a. Determination of  λ-max for ticagrelor 
b. Calibration of ticagrelor in phosphate buffer pH6.8 
II. COMPATIBILITY STUDIES FOR DRUG AND EXCIPIENTS 
a. Fourier transform Infra-Red Spectroscopic (FTIR) studies 
b. Differential Scanning Colorimetry (DSC) studies 
c. X-ray Diffraction (XRD) studies 
III. FORMULATION AND EVALUATION OF SOLID DISPERSION  
a. Formulation of solid dispersion 
b. Estimation of percentage yield and drug content 
c. Invitro dissolution studies 
d. Selection of best formulations 
IV. PEREFORMULATION EVALUATION OF POWDER BLEND 
a. Angle of repose 
b. Bulk density 
c. Tapped density 
d. Carr’s index (I) or % compressibility index 
e. Hausner’s ratio 
V. FORMULATION OF TICAGRELOR SUBLINGUAL TABLETS 
a. By direct compression 
VI. EVALUATION OF POST COMPRESSION PARAMETERS OF 
SUBLINGUAL TABLETS 
a. General appearance 
b. Tablet thickness and diameter 
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c. Hardness 
d. Weight variation test 
e. Friability 
f. Uniformity of drug content 
g. Water absorption ratio 
h. Wetting time 
i. Invitro drug release study  
j. Invitro disintegration time 
VII. EFFECT OF DIFFERENT SUPERDISINTEGRANT ON RELEASE 
PROFILE OF TICAGRELOR SUBLINGUAL TABLETS 
VIII. COMPARISION OF DISSOLUTION DATA OF TICAGRELOR 
SUBLINGUAL  
TABLETS CONTAINING DIFFERENT SUPERDISINTEGRANT 
IX. SELECTION OF BEST FORMULATION 
X. EVALUATION OF SELECTED FORMULATION 
a. Differential scanning colorimetry (DSC) study 
b. Fourier transform infra-red (FTIR) spectroscopic study 
c. Powder X-ray Diffraction(PXRD) study 
XI. DRUG RELEASE KINETIC MODEL 
XII. STABILITY STUDIES 
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MATERIALS AND SUPPLIERS 
 
MATERIALS 
MANUFATURERS / 
SUPPLIERS 
USE IN 
FORMULATION 
Ticagrelor 
Drug Testing Laboratory, 
Chennai 
Acive ingredient 
PEG 6000 Madras pharma, chennai Hydrophilic polymer 
Sodium starch glycolate Madras pharma, chennai Superdisintegrant 
Crosscarmellose 
sodium 
Madras pharma, chennai Superdisintegrant 
Crosspovidone Sai Mirrah innopharma Superdisintegrant 
Microcrystalline 
cellulose 
Sai Mirrah innopharma Diluent 
Saccharin sodium Madras phrama, chennai Sweetening agent 
Mannitol Madras pharma,chennai Diluent 
Talc Madras pharma, chennai Glident 
Magnesium stearate Sai Mirrah innopharma Lubricant 
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INSTRUMENTS /EQUIPMENTS AND SUPPLIERS 
 
EQUIPMENTS / INSTRUMENTS MANUFACTURERS / SUPPLIERS 
Electronic Weighing Balance A & D Company, Japan 
UV Visible spectrophotometer Shimadzu UV – 1800, Japan 
Fourier Transform Infrared Spectroscopy Shimadzu, Japan 
Hot air oven Induatrial headers, Chennai 
Digital Vernier Calliper Linker, Mumbai 
Monsanto Hardness Tester Erweka, Mumbai 
Friability test apparatus Indian equipment corporation 
Disintegration apparatus Rolex, India 
Dissolution apparatus Lab India Disso Apparatus 
Stability Chamber In labs Equipment(Madras) Pvt.Ltd 
12-Station D/B Tooling Compression 
Machine 
Fluid Pack, Ahmedabad 
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DRUG PROFILE 
 
TICAGRELOR 
Ticagrelor is a platelet aggregation inhibitor. It is used for the 
prevention of thrombotic events like stroke, heart attack in people with acute 
coronary syndrome or myocardial infarction with ST elevation.  
Therapeutic category 
Antithrombotic agent.                                                                                                                     
Chemical name 
(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-
propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-
1,2-diol. 
 
CHEMICAL STRUCTURE 
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EMPIRICAL FORMULA                        
 C23H28F2N6O4S 
MOLECULAR WEIGHT                           
 522.6 g/mol 
PHARMACOLOGIC CLASS                    
  P2Y12  receptor antagonist. 
  Adenosine Diphosphate  (ADP) receptor inhibitor. 
DESCRIPTION 
 Physical State : Solid 
 Colour : A white or off-white to pale pink 
 Nature : Non hygroscopic, crystalline powder 
 Melting Point : 138 – 1400 C 
 LogP :  2.31 
 Bioavailability :  36% 
 Solublility :  Soluble in methanol, ethanol, DMSO, dimethyl 
      formamide (DMF) 
 Water solubility :  10 µg/ml (practically insoluble in water). 
 Dose :  60 to 180 mg twice a day orally for one year 
 Usual strength :  60mg; 90 mg. 
 
PHARMACOLOGY 
Mechanism of action 
           Ticagrelor, a member of the chemical class 
cyclopentyltriazolopyrimidines  (CPTP), which is an oral, direct acting 
selective and reversibly binding P2Y12 receptor antagonist that prevents 
adenosine diphosphate (ADP)-mediated P2Y12 dependent platelet activation 
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and aggregation. Ticagrelor does not prevent ADP binding but when bound to 
the P2Y12 receptor prevents ADP-induced signal transduction. Since platelets 
participate in the initiation and/or evolution of thrombotic complications of 
atherosclerotic disease, inhibition of platelet function has been shown to 
reduce the risk of cardiovascular events such as death, myocardial infarction 
or stroke. Ticagrelor has no clinically significant direct effect on adenosine 
receptors (A1, A2A, A2B, A3) and is not metabolized to adenosine. 
 
 
Figure. Mechanism of Action of P2Y12 Inhibitors 
 
PHARMACOKINETICS 
                Ticagrelor demonstrates linear pharmacokinetics. Exposure to 
ticagrelor and active metabolite AR-C124910XX are approximately dose 
proportional. 
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Absorption 
               Absorption of ticagrelor is rapid with a median tmax of approximately 
1.5 hours. The formation of the major circulating metabolite AR-C124910XX 
(also active) from ticagrelor is rapid with a median tmax of approximately 2.5 
hours. The Cmax and AUC of ticagrelor and the active metabolite increased in 
an approximately proportional manner with dose over the dose range studied 
(30-1260 mg).  
               The mean absolute bioavailability of ticagrelor was estimated to be 
36%, (range 25.4% to 64.0%). Ingestion of a high-fat meal had no effect on 
ticagrelor Cmax or the AUC of the active metabolite, but resulted in a 21% 
increase in ticagrelor AUC and 22% decrease in the active metabolite Cmax. 
These small changes are considered of minimal clinical significance; 
therefore, Ticagrelor can be given with or without food.  
               Ticagrelor as crushed tablets mixed in water, given orally or 
administered through nasogastric tube into the stomach, is bioequivalent to 
whole tablets (AUC and Cmax within 80-125% for ticagrelor and the active 
metabolite). Compared to whole tablets, the geometric least-squares (LS) 
mean concentrations of ticagrelor were higher at 0.5 hour and 1 hour following 
administration of crushed tablets suspended in water and dispersed tablets 
suspended in water administered via NGT, respectively. At two hours post-
dose the geometric LS mean concentrations following administration of the 
crushed tablet suspended in water and the dispersed tablet suspended in 
water administered via NGT were similar to the geometric LS mean 
concentration following administration of the whole tablet. 
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Distribution  
The steady state volume of distribution of ticagrelor is 87.5 L. 
Ticagrelor and the active metabolite is extensively bound to human plasma 
protein (>99.0%).  
 
Metabolism  
CYP3A is the major enzyme responsible for ticagrelor metabolism and 
the formation of the active metabolite and their interactions with other CYP3A 
substrates ranges from activation through to inhibition. Ticagrelor and the 
active metabolite are P-glycoprotein weak inhibitors. The major metabolite of 
ticagrelor is AR-C124910XX, which is also active as assessed by in vitro 
binding to the platelet P2Y12 ADP-receptor. The systemic exposure to the 
active metabolite is approximately 30-40% of that obtained for ticagrelor. 
 
Excretion  
   The primary route of ticagrelor elimination is via hepatic metabolism. 
When radiolabelled ticagrelor is administered, the mean recovery of 
radioactivity is approximately 84% (57.8% in faeces, 26.5% in urine). 
Recoveries of ticagrelor and the active metabolite in urine were both less than 
1% of the dose. The primary route of elimination for the active metabolite is 
mostly via biliary secretion. The mean t1/2 was approximately 6.9 hours 
(range 4.5-12.8 hours) for ticagrelor and 8.6 hours (range 6.5-12.8 hours) for 
the active metabolite.  
Clearance of ticagrelor 
The systemic clearance of ticagrelor is 14.2 L/h. 
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ADVERSE EFFECTS 
 Shortness of breath (dyspnea, 14%) and various types of bleeding, such 
as hematoma, nosebleed, gastrointestinal, subcutaneous or dermal bleedi
ng 
 Ventricular pauses of 3 seconds occur in 5 percent of people in the first 
week of treatment.  
 Ticagrelor should be administered with caution or avoided in patients with 
advanced sinoauricular disease. 
 Allergic skin reactions such as rash and itching have been observed in 
less than 1% of patients.  
 
INDICATIONS  
 Ticagrelor, in combination with aspirin, is indicated for the prevention of 
atherothrombotic events (cardiovascular death, myocardial infarction and 
stroke). 
 In adult patients with acute coronary syndromes (unstable angina [UA], 
non ST elevation Myocardial Infarction [NSTEMI] or ST elevation 
Myocardial Infarction [STEMI]) including patients managed medically, and 
those who are managed with percutaneous coronary intervention (PCI) or 
coronary artery by-pass grafting (CABG).  
 
CONTRAINDICATIONS  
 Active pathological bleeding,  
 History of intracranial haemorrhage,  
 Moderate to severe hepatic impairment,  
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 Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g. 
ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is 
contraindicated, as co-administration may lead to a substantial increase in 
exposure to ticagrelor. 
 
DRUG INTERACTIONS 
 Avoid use with strong CYP3A inhibitors and strong CYP3A inducers. 
Ticagrelor is metabolized by CYP3A4/5. Strong inhibitors substantially 
increase ticagrelor exposure and so increase the risk of adverse events. 
 Strong inducers of CYP3A  substantially reduce ticagrelor exposure and 
so decrease the efficacy of ticagrelor.(Example : rifampin, phenytoin, 
carbamazepine, phenobarbital) 
 Patients receiving more than 40 mg per day of simvastatin or lovastatin 
may be at increased risk of statin-related adverse events because these 
drugs are metabolized by CYP3A4. 
 Ticagrelor inhibits the P-glycoprotein transporter; monitor digoxin levels 
with initiation of or change in Ticagrelor therapy. 
 Use of Ticagrelor  with aspirin maintenance doses above 100 mg reduced 
the effectiveness of  ticagrelor. 
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EXCIPIENT PROFILE 
MICROCRYSTALLINE CELLULOSE 
Synonyms : 
 Avicel PH 
 Crystalline cellulose  
 Cellet 
 Emcocel  
 Hellulosum microcristalinum 
 
Chemical name: 
 Cellulose  
 
Empirical  formula: 
 (C6H10O5)n 
 
Molecular weight: 
 36000 gm/mol 
 
Functional category: 
 Adsorbent  
 Suspending agent  
 Tablet and capsule diluents 
 Tablet disintegrant 
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Structural formula: 
 
 
Application in pharmaceutical formulation or technology:  
 Microcrystalline cellulose is widely used in pharmaceuticals primarily as 
binder / diluents in oral tablets and capsule formulation. 
 Micerocrystalline cellulose is also used in cosmetics and food products. 
 
Description : 
 Microcrystalline cellulose is a white, odorless, tasteless, crystalline 
powder composed of polrous particles. 
 
Melting Point: 
 260-2700C 
 
Solubility : 
 Slightly soluble in 5% w/v NaOH  solution, practically insoluble in water 
and most organic solvents.  
 
Solubility and storage condition:  
 Microcrystalline cellulose is stable though hygroscopic material. 
 It should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities: 
 Microcrystalline cellulose is incompatible with strong oxidizing agent. 
 
Handling Precautions: 
 Microcrystalline cellulose may be irritant to the eyes, Gloves, eye 
protection and dust mask are recommended.  
(Hand book of pharmaceutical Excipient by Raymond C Rowe.,5th 
Edition) 
 
POLYETHYLENE GLYCOL 6000 
 Polyethylene glycol 6000 (PEG) is a polyether compound. The 
structure of PEG is HO-CH2-(CH2-O-CH2-)n-CH2-OH 
 PEG is also known as polyethylene oxide (PEO) or polyoxyethylene 
(POE), depending on its molecular weight. 
Structure 
 
Nonproprietary Names 
 Carbowax, GoLYTELY 
 GlycoLax, Fortrans 
 TriLyte, Colyte 
 Halflytely, 
 Macrogol, 
 MiraLAX 
CHAPTER VIII                                                                   EXCIPIENT PROFILE 
 
Dept of Pharmaceutics, College of Pharmacy, MMC, Madurai-20 Page 81 
 
Synonyms 
 PEG; Macrogol;  
 Polyoxyethlene; Aquaffin; 
 Nycoline alpha-hydro-omega-hydroxypoly(oxy-1,2-ethanediyl); 
 polyethylene glycols; Poly Ethylene Oxide; Polyoxyethylene; 
 Polyglycol; 1,2-ethanediol Ehoxylated;  
 Polyoxyethylene ether; 
 Polyoxyethylene; Poly(ethylene glycol); 
 
Chemical Name and CAS Registry Number 
 a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) [25322-68-3] 
 
Empirical Formula and Mol. Weight 
 H(OCH2CH2)nOH [average 6000 g/mol ] 
 
Functional Category 
 Lubricating agent,  
 solubilizing agent,  
 coating agent 
 
DESCRIPTION: 
 Boiling Point   : Min. 250°C (1013 hPa) 
 Melting Point   : 55 to 62 °C 
 Density   : 1.13 g/cm³ (20°C) 
 Appearance    : White or almost white, waxy or paraffin-like 
 Solubility    : Soluble in water 
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Applications in Pharmaceutical Formulation or Technology 
Chemical uses 
 Polyethylene glycol has a low toxicity and is used in a variety of 
products. The polymer is used as a lubricating coating for various 
surfaces in aqueous and non-aqueous environments.  
 Since PEG is a flexible, water-soluble polymer, it can be used to create 
very high osmotic pressures (on the order of tens of atmospheres).  
 Polyethylene glycol is also commonly used as a polar stationary phase 
for gas chromatography, as well as a heat transfer fluid in electronic 
testers. 
 In addition, PEG is used when working with green wood as a stabilizer, 
and to prevent shrinkage. 
 PEG is often used (as an internal calibration compound) in mass 
spectrometry experiments, with its characteristic fragmentation pattern 
allowing accurate and reproducible tuning. 
 PEG derivatives, such as narrow range ethoxylates, are used as 
surfactants. 
 PEG has been used as the hydrophilic block of amphiphilic block 
copolymers used to create some polymersomes. 
 
Industrial uses 
 Nitrate ester-plasticized polyethylene glycol is used in Trident II ballistic 
missile solid rocket fuel. 
 Dimethyl ethers of PEG are the key ingredient of Selexol, a solvent 
used by coalburning, integrated gasification combined cycle (IGCC) 
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power plants to remove carbon dioxideand hydrogen sulfide from the 
gas waste stream. 
 PEG has been used as the gate insulator in an electric double-layer 
transistor to induce 
 superconductivity in an insulator. 
 PEG is also used as a polymer host for solid polymer electrolytes. 
Although not yet in commercial production, many groups around the 
globe are engaged in research on solid polymer electrolytes involving 
PEG, with the aim of improving their properties, and in permitting their 
use in batteries, electro-chromic display systems, and other products in 
the future. 
 
Safety 
 Polyethylene glycols are widely used in a variety of pharmaceutical 
formulations. Generally, they are regarded as nontoxic and nonirritant 
materials. Adverse reactions to polyethylene glycols have been 
reported, the greatest toxicity being with glycols of low molecular 
weight. 
 However, the toxicity of glycols is relatively low. 
 
Handling Precautions  
 Observe normal precautions appropriate to the circumstances and 
quantity of material handled. 
 Eye protection is recommended. 
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MANNITOL 
Synonym: 
 Cordycepic acid 
 Manna sugar 
 D- mannite 
 Mannogem 
 Pearlitol 
Chemical Name:   Mannitol  
Empirical Formula:   C6H14O6 
Molecular Weight:   182.17 
Structural Formula: 
 
Functional Category: 
 Diluents 
 Sweetening agent 
 Tonicity agent 
Applications: 
 It is used as a diluent in tablet formulations. (10-90% w/v) 
 It is used in pharmaceutical formulations and food products. 
 It is used in tablet applications include antacid preparation 
glyceryltrinitrite tablets and vitamin preparations. It is used as an 
excipient in the manufacture of chewable tablet formulation. 
 It is also used in sweetness and mouth feel due to its negative heat of 
solution. 
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 In lyophilized preparations, mannitol (20-90%w/w) had been 
included as a carrier to produce a stiff, homogenous cake that 
improves the appearance of the lyophilized plug in vial. 
 It is used in food application as a bulking agent. 
 Mannitol administered parentally is used as an osmotic diuretic, it is 
used in diagnostic agent for kidney function, as an adjunct in the 
treatment of acute renal failure. 
 
Description: 
 
 Mannitol occurs as a white, odourless, crystalline powder or free 
flowing granule. 
 It has a sweet taste, approximately as sweet glucose and half as 
sweet as sucrose and imparts a cooling sensation in the mouth. 
 Mannitol was found to reduce the oral bio availability of cimetidine 
compared to sucrose. 
 Mannitol is reducing sugar, impurities have been implicated in the 
oxidative degradation of a peptide in a lyophilized formation. 
 
Handling precautions: 
Mannitol is irritant to the eyes; eye protection is recommended. 
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CROSSPOVIDONE 
Synonym: 
 Cross linked povidone 
 Kollido  
 1-vinyl-2-pyrrolidone homopolymer 
 Polyplasdone  
 Polyvinylpolypyrrolidone  
 
Chemical name : 
 1-Ethylene-2-pyrrolidinone homopolymer 
 
Functional formula : 
    
Empirical formula: 
 (C6H9NO)n 
 
Molecular weight: 
 >1000 000 
 
Functional category: 
 Tablet disintegrant. 
 
Application in pharmaceutical formulation or technology: 
 Tablet disintergrant and dissolution agent. 
 Solubility enhancer for poorly soluble drug  
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Description: 
 Crosspovidone is a white-creamy white 
 Free flowing 
 Practically tasteless 
 Hygroscopic powder 
 
Melting Point: 
 150OC 
 
Stability and Storage condition: 
 Crosspovidone is hygroscopic. 
 It should be stored in an airtight container in a cool, dry place. 
 
Incompatibilities: 
 Crosspovidone is compatible with most organic and inorganic 
pharmaceutical ingredients. 
 When exposed to a high water level. 
 Crosspovidone may form molecular adduct with some materials. 
 
Handling Precautions: 
 Observe normal precaution appropriate to the circumstances and 
quantity of material handled. 
 Eye protection gloves and a dust mask are recommended  
(Hand  book of Pharmaceutical Excipients by Raymond C Rowe 5th Edition.) 
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TALC 
Synonym: 
  Altalc 
  Hydrous magnesium calcium silicate 
  Hydrous magnesium silicate 
 
Chemical name: 
  Talc 
  Purified talc 
  Talcum 
 
Empirical Formula: 
 Talc is purified, hydrated, magnesium silicate. 
  Mg6 ((Si2O5)4(OH) 4) 
  It may contain small variable amounts of silicate and iron. 
 
Molecular weight: 
 379.27 
 
Structural Formula: 
    
Functional Category  
 Anticaking agent 
 Glidant 
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 Diluent 
 Lubricant 
 
Application in pharmaceutical formulation or technology: 
 Talc is widely used in solid dosage formulations. 
 Lubricant and Glidant. (1.0-10.0) 
 Diluents in tablet and capsule. (5.0-30) 
 It is widely used as a dissolution retardant in the development of 
controlled-release products. 
 Talc is novel powder coating for extended release pellets and as an 
adsorbent. 
 It is used as a dusting powder. (concentration 90.0-99.0) 
 It is used to clarify liquids and is used in cosmetics and food products. 
 It is used in baby powder. 
 
Description: 
 Talc is very fine, white to grey-white, odourless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to touch 
and free from grittiness. 
 
Melting Point: 
 800oC 
 
Solubility: 
 Practically insoluble in organic solvent, water and in dilute acids & 
alkalis. 
 
CHAPTER VIII                                                                   EXCIPIENT PROFILE 
 
Dept of Pharmaceutics, College of Pharmacy, MMC, Madurai-20 Page 90 
 
Stability and Storage condition: 
 Talc is a stable material and may be sterilized by heating at 160oC for 
not less than one  hour. 
 It may also be sterilized by exposure to ethylene oxide or gamma 
radiation. 
 Talc should be stored in well closed container in a cool, dry place. 
 
Incompatibilities: 
 Incompatible with quaternary ammonium compounds. 
 
Handling Precautions: 
 Talc is irritant if inhaled and prolonged exposure may cause 
pneumoconiosis. 
 In the UK, the occupational exposure limit for talc is long-term (8 hour 
TWA). Eye protection, gloves and respirator are recommended. 
(Hand book of  Pharmaceutical Excipients by Raymond C Rowe.,5th Edition) 
 
MAGNESIUM STEARATE 
Synonym: 
 Magnesium octadecanoate 
 Octadecanoic acid 
 Magnesium salt 
 Stearic acid 
 Magnesium salt 
 
Chemical Name: 
 Octadecanoic acid magnesium salt (557-04-0) 
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Empirical Formula: 
 Magnesium stearate as a compound of magnesium with a mixture of 
solid organic acids that consists of variable proportions of magnesium 
stearate and magnesium palmitate. 
 Magnesium stearate : C36 H20 MgO4 
 Magnesium palmitate : C32 H62 MgO4 
 
Molecular weight: 
 591.34 
Structural Formula: 
 
Functional Category: 
 Tablet and capsule lubricant. 
 
Application inpharmaceutical Formulation or Technology: 
 It is widely used in cosmetics, foods and pharmaceutical formulations.  
  It is used as a lubricant in capsule and tablet manufacture at 
concentrations 0.25% and 5.0% w/w. 
 
Description : 
 Magnesium Stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low density, having a faint odour of stearic acid 
and a characteristic taste. 
  The powder is greasy to touch and readily adheres to the skin 
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Melting Point: 
 117-150OC 
 
Solubility: 
 Slightly soluble in warm benzene and warm ethanol. 
 Practically insoluble in ethanol and water. 
 
Stability and Storage condition: 
 Magnesium stearate is stable and should be stored in well closed 
container in a cool, dry place 
 
Incompatibilities: 
 Incompatible with strong acids, alkalis and iron salts. 
 Magnesium stearate cannot be used with aspirin, some vitamin and 
most alkaloidal salts. 
 
Handling Precautions: 
 Eye protection and gloves are recommended. 
 Excessive inhalation of magnesium stearate dust may cause upper 
respiratory tract discomfort, coughing and choking. 
(Hand book of Pharmaceutical Excipients by Raymond C 
Rowe.,5thEdition). 
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CROSSCARMELLOSE SODIUM 
Synonyms:  
 Ac-Di-Sol;  
 carmellosum natricum conexum;  
 crosslinked carboxymethylcellulose sodium;  
 Explocel; modified cellulose gum;  
 Nymcel ZSX; Pharmacel XL;  
 Primellose; Solutab; Vivasol 
 
Chemical name:       
 Cellulose,  
 carboxymethyl ether,  
 sodium salt, crosslinked 
 
Structure: 
 
Chemical formula:    
 C8H16O8 
 
Functional uses:  
 Tablet and capsule disintegrant.       
 
 
CHAPTER VIII                                                                   EXCIPIENT PROFILE 
 
Dept of Pharmaceutics, College of Pharmacy, MMC, Madurai-20 Page 94 
 
Description:   
 Crosscarmellose sodium occurs as an odorless, white or grayish white 
powder. 
 
Applications in Pharmaceutical Formulation or Technology:  
 Crosscarmellose sodium is used in oral pharmaceutical formulations 
as a disintegrant for capsules, tablets, and granules.  
 In tablet formulations, crosscarmellose sodium may be used in both 
direct-compression and wet-granulation processes. When used in wet 
granulations, the crosscarmellose sodium should be added in both the 
wet and dry stages of the process (intra- and extragranularly) so that 
the wicking and swelling ability of the disintegrant is best utilized.  
 Crosscarmellose sodium at concentrations up to 5% w/w may be 
used as a tablet disintegrant, although normally 2% w/w is used in 
tablets prepared by direct compression and 3% w/w in tablets 
prepared by a wet-granulation process 
 
Stability and Storage Conditions:  
 Crosscarmellose sodium is a stable though hygroscopic material. A 
model tablet formulation prepared by direct compression, with 
crosscarmellose sodium as a disintegrant, showed no significant 
difference in drug dissolution after storage at 30 8C for 14 months.  
 Crosscarmellose sodium should be stored in a well-closed container 
in a cool, dry place 
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Incompatibilities:  
 The efficacy of disintegrants, such as crosscarmellose sodium, may 
be slightly reduced in tablet formulations prepared by either the wet-
granulation or direct-compression process that contain hygroscopic 
excipients such as sorbitol. Crosscarmellose sodium is not compatible 
with strong acids or with soluble salts of iron and some other metals 
such as aluminum, mercury, and zinc. 
 
Safety:  
 Crosscarmellose sodium is mainly used as a disintegrant in oral 
pharmaceutical formulations and is generally regarded as an 
essentially nontoxic and nonirritant material.  
 However, oral consumption of large amounts of crosscarmellose 
sodium may have a laxative effect, although the quantities used in 
solid dosage formulations are unlikely to cause such problems. 
 
SODIUM STARCH GLYCOLATE 
Nonproprietary Names 
 BP: Sodium Starch Glycolate 
 PhEur: Sodium Starch Glycolate 
 USP-NF: Sodium Starch Glycolate 
 
Synonyms 
 Carboxymethyl starch, 
 sodium salt; 
 carboxymethylamylum natricum; 
 Explosol; 
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 Explotab;  
 Glycolys; Primojel; 
 starch carboxymethyl ether,  
 sodium salt; Tablo; Vivastar P. 
 
Chemical Name  
 Sodium carboxymethyl starch  
 
Empirical Formula  
 C2H4O3 x Na x-Unspecified 
 
Fragment 
 C2H4O3 Component  Na  Unspecified 
 
Molicular weight 
 Sodium starch glycolate may be characterized by the degree of 
substitution and crosslinking. The molecular weight is typically 5 x105 – 
1 x 106. 
 
Structural Formula 
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Functional Category 
 Tablet and capsule disintegrant. 
 
Applications in Pharmaceutical Formulation or Technology 
 Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations.  
 It is commonly used in tablets prepared by either direct-compression or 
wet-granulation processes.  
 The usual concentration employed in a formulation is between 2% and 
8%, with the optimum concentration about 4%, although in many cases 
2% is sufficient..  
 Increasing the tablet compression pressure also appears to have no 
effect on disintegration time.  
 Sodium starch glycolate has also been investigated for use as a 
suspending vehicle. 
 
Description 
 Sodium starch glycolate is a white or almost white free-flowing very 
hygroscopic. 
 
Melting point  
 Does not melt, but chars at approximately 2000C 
 
Solubility 
 Practically insoluble in methylene chloride. It gives a translucent 
suspension in water. 
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Stability and Storage Conditions 
 Tablets prepared with sodium starch glycolate have good storage 
properties.  
 Sodium starch glycolate is stable although very hygroscopic, and 
should be stored in a well-closed container in order to protect it from 
wide variations of humidity and temperature, which may cause caking.  
 The physical properties of sodium starch glycolate remain unchanged 
for up to 3 years if it is stored at moderate temperatures and humidity. 
 
Incompatibilities 
 Sodium starch glycolate is incompatible with ascorbic acid. 
 
Safety  
 Sodium starch glycolate is widely used in oral pharmaceutical 
formulations and is generally regarded as a nontoxic and nonirritant 
material. However, oral ingestion of large quantities may be harmful  
 
Handling Precautions 
 Observe normal precautions appropriate to the circumstances and 
quantity of material handled.  
 Sodium starch glycolate may be irritant to the eyes; eye protection and 
gloves are recommended.  
 A dust mask or respirator is recommended for processes that generate 
a large quantity of dust. 
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SACCHARIN SODIUM 
 
Nonproprietary Names 
 BP: Saccharin Sodium 
 JP: Saccharin Sodium Hydrate 
 PhEur: Saccharin Sodium 
 USP: Saccharin Sodium 
 
Synonyms 
 1,2-Benzisothiazolin-3-one 1,1-dioxide,  
 sodium salt; Crystallose; 
 E954; gendorf 450;  
 saccharinum natricum;  
 sodium o-benzosulfimide; 
 soluble gluside; soluble saccharin;  
 sucaryl sodium. 
 
Chemical Name  
 1,2-Benzisothiazol-3(2 H )-one 1,1-dioxide 
 
Empirical Formula and Molecular Weight 
 C7 H4 NNaO3 S   205.16 
 C7 H4 NNaO3 S. 1 2⁄ H2O (84%)  217.24 
 C7 H4 NNaO3 S. 2H2O (76%)  241.19  
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Structural Formula 
 
 
 
Functional Category 
 Sweetening agent. 
 
Applications in Pharmaceutical Formulation or Technology 
 Saccharin sodium is an intense sweetening agent used in beverages, 
food products, table-top sweeteners, and pharmaceutical formulations 
such as tablets, powders, medicated confectionery, gels, suspensions, 
liquids, and mouthwashes.  
 It is also used in vitamin preparations.  
 Saccharin sodium is considerably more soluble in water than 
saccharin, and is more frequently used in pharmaceutical formulations.  
 Its sweetening power is approximately 300–600 times that of sucrose. 
Saccharin sodium enhances flavor systems and may be used to mask 
some unpleasant taste characteristics.  
 Injection of saccharin sodium has been used to measure the arm to- 
tongue circulation time. 
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Uses of saccharin sodium 
 Dental paste/gel  0.12–0.3% 
 IM/IV injections  0.9% 
 Oral solution   0.075–0.6% 
 Oral syrup   0.04–0.25% 
 
Description 
 Saccharin sodium occurs as a white, odorless or faintly aromatic, 
efflorescent, crystalline powder.  
 It has an intensely sweet taste, with a metallic or bitter after taste that 
at normal levels of use can be detected by approximately 25% of the 
population. The aftertaste can be masked by blending saccharin 
sodium with other sweeteners. Saccharin sodium can contain variable 
amounts of water. 
 
Melting point  
 Decomposes upon heating. 
 228.80 C 
 
Stability and Storage Conditions 
 Saccharin sodium is stable under the normal range of conditions 
employed in formulations.  
 Only when it is exposed to a high temperature 1250C at a low pH (pH 
2) for over 1 hour does significant decomposition occur. The 84% 
grade is the most stable form of saccharin sodium since the 76% form 
will dry further under ambient conditions.  
 Solutions for injection can be sterilized by autoclave.  
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 Saccharin sodium should be stored in a well-closed container in a dry 
place. 
 
Incompatibilities 
 Saccharin sodium does not undergo Maillard browning. 
 
Safety 
 There has been considerable controversy concerning the safety of 
saccharin and saccharin sodium in recent years; however, it is now 
generally regarded as a safe, intense sweetener.  
 The WHO has set a temporary acceptable daily intake of up to 2.5 
mg/kg body-weight for saccharin, including its salts.  
 In the UK, the Committee on Toxicity of Chemicals in Food, Consumer 
Products, and the Environment (COT) has set an acceptable daily 
intake for saccharin and its salts (expressed as saccharin sodium) at 
up to 5 mg/kg body-weight. 
 
Handling Precautions 
 Observe normal precautions appropriate to the circumstances and 
quantity of material handled.  
 Eye protection and a dust mask are recommended.  
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EXPERIMENTAL PROTOCOL 
 
 Colour and Appearance:  (Indian Pharmacopoeia, 2018) 
The sample was observed visually. 
 Melting Point: (Indian Pharmacopoeia, 2018) 
Melting point of drug was determined by Melting point test apparatus. 
Solubility: (Indian Pharmacopoeia, 2018) 
Solubility study was carried out as per the I.P.2018.In this maximum 
amount of solvent required to dissolve the solute was determined. 
PREPARATION OF BUFFER SOLUTION (Indian Pharmacopoeia, 2014) 
Preparation of pH 6.8 phosphate buffer solution 
Take 50 ml of 0.2M Potassium Dihydrogen phosphate in a200ml 
volumetric flask and add 22.4ml of 0.2M Sodium hydroxide solution, then the 
volume was made upto 200ml using distilled water.         
                                                                                                                    
Preparation of 0.2M potassium dihydrogen phosphate 
27.218g of potassium dihydrogen phosphate was dissolved in distilled 
water and the volume was made up to 1000 using distilled water.         
                           
Preparation of 0.2M sodium hydroxide 
 8g of sodium hydroxide was dissolved in distilled water and made up to 
1000ml with distilled water. 
 
DETERMINATION OF MAXIMUM ABSORPTION (λ MAX) 
 The standard stock solution of ticagrelor having concentration 10µg/ml 
is prepared by dissolving 10mg of ticagrelor in 5ml methanol and diluted with 
phosphate buffer pH 6.8 up to 10 ml. The stock solution is further diluted 
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using phosphate buffer to produce 10µg/ml concentration. The resultant 
solution is scanned between wavelength of 200-400nm by UV 
spectrophotometer to get maximum absorption (λmax). (Ranjan Kumar et 
al.2016) 
 
PREPARATION OF STANDARD CALIBRATION CURVE FOR 
TICAGRELOR: 
 From the above stock solution, aliquots are taken into different 
volumetric flasks and volume are made up to 10 ml with phosphate buffer PH 
6.8 solution, so as to get concentration of  2, 4, 6, 8, 10, 12, 14, 16, 18, 20 
µg/ml. The absorbance of these solution is measured at 295 nm by UV 
spectrophotometer. A calibration curve is plotted by taking concentration on 
X- axis and absorbance on Y-axis to obtain the standard curve. 
 
DRUG- EXCIPIENTS COMPATIBILITY STUDIES 
Fourier Transform infrared (FTIR) spectroscopy studies: 
  FT–IR spectra were recorded for ticagrelor pure drug and physical 
mixture using IR spectrophotometer. The samples were prepared in KBr dish 
and scanned over 400 to 4000 cm-1 (Rajendra B. Kakde et al. 2017) 
 
 Differential scanning colorimetric (DSC) studies 
Differential scanning calorimetry was used to characterize thermal 
properties of ticagrelor and other excipients. Shimadzu TA – 60WS thermal 
analyzer was used to obtain DSC measurements. Required amount of 
sample(about 2mg) were placed in flat bottomed aluminium pans(0.1mm 
thickness) and then crimped with an aluminium lid. Then the samples were 
placed into sample holder and allowed to heat from 25 to 300 ˚C at a fixed 
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heating rate (10 ˚C per minute) under a nitrogen flow (10cc/minute). The 
temperature calibration of the instrument was carried out using indium 
standard, the same heating rate and pan type used for the study. Heat flow 
and heat capacity signals were calibrated using powdered alumina (5mg, 
100mesh) as a reference. (Nazare et al. 2017) 
 
FORMULATION AND EVALUATION OF SOLID DISPERSION: 
a. Formulation of solid dispersion: 
 In this method is based on the hydrophilic polymer is heated and 
convert into a paste. The drug is then added to the above paste for a 
specified time. Then the mixture is dried and passed through a sieve if 
required. Four formulations (A1 to A4) of ticagrelor solid dispersion were 
prepared in different ratios of drug: carrier 1:1, 1:2, 1:3, and 1:4 and their drug 
content and percentage yield is estimated. 
 
b. Estimation of percentage yield and drug content: 
 Percentage yield is calculated to know about percent of yield 
obtained or efficiency of method. Thus it helps in selection of appropriate 
method of production. It is found out by dividing the practical mass to the 
theoretical mass of the solid dispersion. The physical mixtures and solid 
dispersion equivalent to 10mg of ticagrelor are weighed accurately and 
dissolved in 10ml of ethanol. The solution is filtered, diluted suitably and drug 
content is analysed at λmax of 295nm by UV spectrophotometer. 
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c. Invitro dissolution studies:  
 Invitro dissolution studies of pure drug ticagrelor, physical mixture and 
solid dispersion are performed by using dissolution test apparatus USP type-II 
at a paddle rotation speed of 50 in 900ml of phosphate buffer pH6.8 in 
distilled water and temperature is maintained at 37 ± 0.50 C. Samples 
equivalent to 10mg of ticagrelor is filled in hard gelatin capsule. Samples are 
collected at regular intervals of time (10, 20, 30, 40, 50, 60 minutes). The 
absorbance of samples are measured at 295nm after suitable dilution. 
 
SELECTION OF BEST FORMULATION: 
 The selection of best formulation is done based on percentage yield, 
drug content and release rate of ticagrelor invitro dissolution studies. 
 
EVALUATION OF SELECTED FORMULATION: 
Powder X-ray diffraction (PXRD) studies: 
Rigakuminiflex 600 X-ray diffractometer (Rigaku Co., Tokyo, Japan), 
operated at 600 watts (X-ray tube), with a fixed tube current (15 mA) and a 
fixed voltage(40 kV) was used to achieve the X-ray powder diffraction pattern. 
The X-ray beam(diffracted) was monochromated by a graphite 
monochromator and detection was carried out by a standard scintillation 
counter. Diffraction intensities were measured over a peak range of 5–80° 
(2θ)..Powder X-ray diffraction is a unique method in determination of of a 
compound. It is used in distinguishing between amorphous and crystallinity 
crystalline material. Crystal is composed of periodic arrangement of atoms 
whereas amorphous atoms do not possess that periodicity. When there is 
periodic arrangement of atoms, the x-ray will be scattered only in certain 
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direction. This will cause high intensity peaks. In amorphous phase, x-rays 
will be scattered in many direction leading to large bump distributed in a wide 
range instead of high intensity narrower peak. (Nazare et al. 2017)  
  
Fourier transform infrared (FTIR) spectroscopic studies: 
   FT–IR spectra were recorded for ticagrelor pure drug and solid 
dispersion using IR-spectrophotometer. The samples were prepared in KBr 
dish and scanned over 400 to 4000 cm1. The shift in characteristic bands 
reveal a modification in the drug environment. (Rajendra B.Kakde et al. 
2017) 
 
PRECOMPRESSION EVALUATION OF POWDER BLEND: 
a. Angle of repose: 
 For the angle of repose of the material was poured through a funnel to 
form a cone. The tip of the funnel should be held closed to the growing cone 
and slowly raised as the pile grows, to minimize the impact of falling particles. 
Stop pouring the material when the pile reached a predetermined height or 
the base a predetermined width. Rather than attempt to measure the angle of 
the resulting cone directly, divided the height by half the width of the base of 
the cone. The inverse tangent of this ratio is the angle of repose. It is defined 
as maximum angle possible between surface of the pile of powder and the 
horizontal plane. 
Formula for angle of repose:  
  Tan ɵ = h/ r  
         ɵ =tan-1h/r 
         h  = height of pile, 
         r  = radius of pile 
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b. Bulk density: 
 Bulk density of was determined by taking a known mass of powder in a 
50 ml graduated measuring cylinder which is attached to the bulk density 
apparatus. The bulk density was calculated by following equation, 
Bulk density= 
𝑾𝒆𝒊𝒈𝒉𝒕 𝒐𝒇 𝑷𝒐𝒘𝒅𝒆𝒓
𝑩𝒖𝒍𝒌 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝑷𝒐𝒘𝒅𝒆𝒓
 
 
c. Tapped density 
Tapped density was determined by tapping method using measuring 
cylinder containing weighed amount of powder. The cylinder was dropped 3 
times from a height of 1 inch at an interval of 2 sec. tapped density was 
calculated by following equation.  
Tapped density  =  
𝑴𝒂𝒔𝒔 𝒐𝒇 𝑷𝒐𝒘𝒅𝒆𝒓
𝑻𝒂𝒑𝒑𝒆𝒅 𝒗𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝑷𝒐𝒘𝒅𝒆𝒓
 
                 Dt  = 
𝑴
𝑽𝒕
 
d. Carrs compressibility index 
This is an important property in maintaining uniform weight. It is 
calculated by using following formula.  
%compressibility index =  
𝑻𝒂𝒑𝒑𝒆𝒅 𝒅𝒆𝒏𝒔𝒊𝒕𝒚−𝑩𝒖𝒍𝒌 𝒅𝒆𝒏𝒔𝒊𝒕𝒚
𝑻𝒑𝒑𝒆𝒅 𝒅𝒆𝒏𝒔𝒊𝒕𝒚
 x 100 
e. Hausner’s ratio:  
 A similar index to indicate the flow properties can be defined by        
hausner’s ratio. Hausner’s ratio can be calculated by using following formula:  
Hausner’s ratio = 
𝑻𝒂𝒑𝒑𝒆𝒅 𝑫𝒆𝒏𝒔𝒊𝒕𝒚
𝑩𝒖𝒍𝒌 𝑫𝒆𝒏𝒔𝒊𝒕𝒚
 
H = 
𝑫𝒕
  𝑫𝒃
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Flow Property 
Angle of 
Repose(Ɵ) 
Compressibility   
Index (%) 
Hauser’s 
Ratio 
Excellent 25-30 ˂10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very poor ˃65 ˃38 ˃1.60 
 
 
f. Drug content 
Weight of the powder material equivalent to 100 mg of Ticagrelor is 
dissolved in methanol and transferred into 100 ml volumetric flask. Then 30 
ml of phosphate buffer pH 6.8 is added slowly, mixed properly and the volume 
is made up to 100 ml with phosphate buffer pH 6.8. The above solution is 
filtered and 10 ml of filtrate is taken into 100 ml volumetric flask and made up 
to final volume with phosphate  buffer pH 6.8 and the drug content is 
estimated by measuring the absorbance at λ max 295 nm using a UV 
spectrophotometer. 
 
FORMULATION OF TICAGRELOR SUBLINGUAL TABLETS 
1. Formulation development 
 Sublingual tablets containing 6 mg of model drug were prepared with a 
total tablet weight of 200mg. Considering the preformulation studies and the 
literature survey conducted the excipients were selected and an attempt to 
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produce sublingual tablets with ideal mouth feel maintaining the basic tablet 
properties was made. 
 
2. Selection of superdisintegrants: 
 Short disintegration time with good dispersability is the most important 
characteristics of a sublingual or mouth dispersible tablets. The necessity of a 
Sublingual tablet is to disintegrate within seconds, in limited amount of the 
water available in the form of saliva. Different superdisintegrants 
crosscarmellose sodium, crosspovidone, Sodium starch glycol late in the 
concentration range of 1.5% to 7.5% were used which act as disintegrates 
used at various concentrations and a comparative study was carried out.  
 
3. Selection of diluents 
 Since direct compression method was followed the choice of directly 
compressible diluents was important. Microcrystalline cellulose was selected 
as the filler or diluents owing to its multiple functionality as binder, 
disintegrant, compressibility and flowability. Of the various grades available 
the granular form Avicel PH102 was selected as it had been already reported 
to provide lower crushing strengths and shorter disintegration times. Mannitol 
was selected to produce a cooling and pleasant mouth feel, it was reported 
that mannitol above the concentration of 33% gives good mouth feel, thus 
mannitol in all the batches was fixed at a concentration of 60%. Besides 
mannitol also possesses sweetening properties and reduces the gritty mouth 
feel effect due to microcrystalline cellulose. It also has good compressibility 
properties and solubility in water. 
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4. Selection of additional ingredients 
 The flow property of the pure drug was found to be moderate (Hauser’s 
ratio ~ 1.4) thus to still improve the flow of the blend magnesium stearate 
(0.75%) as lubricant were incorporated also magnesium stearate decreases 
the hardness of tablets without affecting the disintegration time. Saccharin 
sodium was used in the concentration of 0.5% as the sweetener. 
 
5. Formula 
 Sublingual tablets of model drug was formulated using mannitol, Avicel 
pH102 (microcrystalline cellulose) as diluents. Sublingual tablet was prepared 
by direct compression technique as it’s a cost effective method. 
Crosspovidone, Crosscarmellose sodium, Sodium starch glycolate used as a 
superdisintegrant. Sacchari sodium as sweetening agent. Magnesium 
stearate (0.75%) as lubricant and talc (0.75) used as a glident. 
 
6. Formulation of different batches 
The main aim of the present study was to formulate different batches 
using three various superdisintegrants and other ingredients in varying 
concentrations. So different batches of formulations was planned accordingly. 
According to that F1, F2, F3, F4, F5 (with Sodium starch glycolate 1.5%, 3%, 
4.5%, 6%, 7.5%), F6, F7, F8, F9, F10(with Crosscarmellose 1.5%, 3%, 4.5%, 
6%, 7.5%)and F11, F12, F13, F14, F15(with crosspovidone 1.5%, 3%, 4.5%, 
6%, 7.5%).The slight bitter taste of the drug was masked using aspartame 
(2.5% to 6%) as the sweetening agent. 
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Method of formulation 
1. Direct compression method. 
The solid dispersion containing ticagrelor is thoroughly mixed with the 
superdisintegrants, and then other excipients are added to the mixer and 
passed through the sieve (#:60). Collect the powder mixer, blend with 
magnesium stearate (pre sieved), and subject the blend for tablet 
compression. 
 
Representation of Direct Compression Technique for design of 
Sublingual Tablets 
 The drug and the excipients were passed through sieve no: 60 except 
lubricant. The blend was further lubricated with Magnesium stearate (#:60) 
and the powder blend is subjected to drying for removal of moisture content 
and was compressed by direct compression method by using 12 station B/D 
tolling compression machine. Round punches measuring 8.7mm diameter 
were used for compression. Tablet of 200mg was prepared by adjusting 
hardness and volume screw of compression machine properly.(kalyankar et 
al., 2015). 
 
POST COMPRESSIONAL EVALUATION OF TICAGRELOR SUBLINGUAL 
TABLETS 
a. General appearance 
 The general appearance of a tablet, its visual identity and over all 
"elegance" is essential for consumer acceptance. Include in are tablet's size, 
shape, colour, presence or absence of an odour, taste, surface texture, 
physical flaws and consistency and legibility of any identifying marking. 
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b. Tablet thickness & diameter 
 Tablet thickness is an important characteristic in reproducing 
appearance. Tablet thickness and diameter can be measured using a simple 
procedure. 5 tablets were taken and their thickness and diameter was 
measured using digital Vernier calliper.(Pati Vaishali et al.2015) 
 
c. Hardness 
 Hardness of tablet is defined as the force applied across the 
diameter of the tablet in the order to break the tablet. The resistance of the 
tablet to chipping, abrasion or breakage under condition of storage 
transformation and handling before usage depends on its hardness. 
Hardness of the tablet of each formulation was determined using Monsanto 
Hardness tester. (Pati Vaishali et al.2015) 
 
d. Drug Content 
 Randomly ten tablets are selected from formulation, finely powdered 
and powder equivalent mg of drug is accurately weighed and transferred to 
100 ml volumetric flasks containing solution of desired pH. The flask is 
shaken to mix the contents thoroughly. The volume is made up to the mark 
with solution and filtered. One ml of the filtrate is suitably diluted and drug 
content is estimated using a double beam UV-visible spectrophotometer. This 
procedure is repeated thrice and the average value is calculated. (Pati 
Vaishali et al.2015) 
 
e. Uniformity of weight 
 I.P. procedure for uniformity of weight was followed, twenty tablets 
were taken and their weight was determined individually and collectively on a 
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digital weighing balance. The average weight of one tablet was determined 
from the collective weight. (Pati Vaishali et al.2015) 
 
IP Limit For Weight Variation (Indian Pharmacopoeia) 
Average weight of tablet Percentage deviation allowed 
80mg or less ±10 
60mg but ˂ 250 mg ±7.5 
250 mg or more ±5 
 
f. Friability test 
 The friability of tablets is determined using Roche friabilator. Twenty 
tablets are randomly selected from each formulation and initial weight of 20 
tablets are calculated and then transferred into friabilator. The friabilator is 
operated at 25 rpm for 4 minutes (100 revolutions). The tablets are dedusted 
and weighed again (final weight). The percentage friability is calculated by the 
following equation, 
F = 
𝑰𝒏𝒊𝒕𝒊𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕−𝑭𝒊𝒏𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕
𝑭𝒊𝒏𝒂𝒍 𝒘𝒆𝒊𝒈𝒉𝒕
 x 100 
Compress tablet that lose less than 0.1 to 0.8% of the tablet weight are 
consider acceptable. 
 
g. Wetting time (WT) 
 A piece of tissue paper (12 cm X 10.75 cm) folded twice was placed in 
a small petri dish (ID = 6.5 cm) containing 6 ml of Sorenson's buffer pH 6.8. A 
tablet was put on the paper, and the time for complete wetting was measured. 
Three trials for each batch and the standard deviation were also determined. 
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The time required for the water to diffuse from the wetted absorbent paper 
throughout the entire tablet is then recorded using a stopwatch. (Ruchita 
Jaiswani et al. 2014) 
 
h. Water absorption ratio 
 A piece of tissue paper folded twice is placed in a small Petri dish 
Containing 6 ml of water. A tablet is put on the tissue paper and allowed to 
completely wet. The wetted tablet is then weighted. Water absorption ratio, R 
was determined using following equation. (Ruchita Jaiswani et al. 2014) 
R = 
𝑾𝒂−𝑾𝒃
𝑾𝒂
 x 100 
Where, 
Wa = Weight of tablet after water absorption 
Wb = Weight of tablet before water absorption. 
i. Disintegration test 
 A relatively simple method with rigorous conditions is developed. Each 
individual tablet is dropped into 10-ml glass test tube (1.5-cm diameter) 
containing 2ml distilled water, and the time required for complete tablet 
disintegration is observed visually and recorded using a stopwatch. The visual 
inspection is enhanced by gently rotating the test tube at a 450 angle, without 
agitation, to distribute any tablet particles that might mask any remaining no 
disintegrated portion of the tablets. In the USP disintegration test for 
sublingual tablets, the disintegration apparatus for oral tablets is used without 
the covering plastic disks, and 2 minutes is specified as the acceptable limit 
for tablet disintegration. (Ruchita Jaiswani et al. 2014) 
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j. In-vitro dissolution studies 
 Dissolution study was carried out in USP II paddle type apparatus 
using 500 mL of phosphate buffer (pH 6.8) as a dissolution medium at 50 
rpm. Temperature of the dissolution Medium was maintained at 37±0.5ºC. 
Samples of 5ml were withdrawn at every 5 minute Interval, filtered (through 
0.45μ) and replaced with 5ml of fresh dissolution medium. The Samples were 
suitably diluted and estimated spectrophotometrically at 295 nm by using 
Shimadzu-1700 UV-Visible Spectrophotometer. The dissolution experiments 
were conducted in triplicate. Dissolution rate was studied for all designed 
formulations and dissolution parameters were calculated acceptable time limit 
for tablet disintegration. (Ruchita Jaiswani et al. 2014) 
 
  
Parameter Specifications 
Apparatus USP II Paddle 
Dissolution medium 
300ml phosphate buffer 
pH6.8 
Rotation speed 50 rpm 
Temperature 37±0.50C 
Withdrawn sample 5ml 
Sampling interval 5 min 
Absorbance measured 295nm 
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EFFECT OF DIFFERENT SUPERDISINTEGRANT ON RELEASE PROFILE  
OF TICAGRELOR SUBLINGUAL TABLETS 
SELECTION OF BEST FORMULATION  
The selection of best formulation is done based on rate of ticagrelor 
release from the Invitro dissolution release studies. 
 
EVALUATION OF SELECTED FORMULATION 
Fourier Transform infrared (FTIR) spectroscopy studies: 
  FT–IR spectra were recorded for ticagrelor pure drug and physical 
mixture using IR spectrophotometer. The samples were prepared in KBr dish 
and scanned over 400 to 4000 cm-1 
 
Differential scanning colorimetric (DSC) studies 
 Differential scanning calorimetry was used to characterize thermal 
properties of ticagrelor, ticagrelor with PEG-6000 and other excipients. The 
DSC thermograms were recorded using TA-60 thermal analyzer (Schimadzu). 
The samples were hermetically sealed in aluminium pans and heated at a 
constant rate of 20o/min over temperature range of 50 to 2000 C. Inert 
atmosphere was maintained by purging nitrogen gas at flow rate of 50 ml/min. 
 
Powder X-ray diffraction (PXRD) studies 
 Powder X-ray diffraction is a unique method in determination of 
crystallinity of a compound. It is used in distinguishing between amorphous 
and crystalline material. Crystal is composed of periodic arrangement of 
atoms whereas amorphous atoms do not possess that periodicity. When 
there is periodic arrangement of atoms, the x-ray will be scattered only in 
certain direction. This will cause high intensity peaks. In amorphous phase, x-
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rays will be scattered in many direction leading to large bump distributed in a 
wide range instead of high intensity narrower peak. 
 
EVALUATION OF INVITRO RELEASE KINETICS 
 To study the invitro release kinetics of the sublingual tablets, data 
obtained from invitro dissolution study were plotted in various kinetics models. 
 
1. Zero order release rate kinetics 
 The zero order order release kinetics can be obtained by plotting 
cumulative % drug released Vs time (hours). 
C=K0 t 
Where K0 = Zero order constant in conc/time 
 T= time in hours 
 
2. First order release rate kinetics 
 The graph was plotted as log% cumulative drug remaining Vs time in 
hours. 
LogC=logC0 – Kt/2.303 
C0=Initial drug concentration 
K= First order constant 
t = Time in hours  
 
3. Higuchi kinetics 
 The graph was plotted with % cumulative drug released Vs squre 
root of time. 
     Q = K t1/2 
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Where    K= constant reflecting design variable system 
  t= time in hours 
The drug release rate is inversely proportional to the square root of time. 
 
4. Hixson and Crowell erosion equation 
 To evaluate the drug release with changes in the surface area and 
the diameter of particles, the data were plotted using the Hixson and crowell 
erosion equation. The graph was plotted by cube root of % drug remaining Vs 
Time in hours. 
     Q01/3 – Qt1/3 = KHC X t 
Qt = Amount of drug released at time t 
Q0 = Initial amount of drug  
KHC = Rate constant for Hixson crowell equation 
 
5. Korsmeyer – peppas equation 
 To evaluate the mechanism of drug release, it was further plotted in 
peppas equation as log cumulative % of drug released Vs log time. 
     Mt / Mα = K tn 
Where, Mt / Mα = Fraction of drug release at time t 
t = release time 
K= Kinetics constant 
N=Diffutional exponent indicative of the mechanism of drug release 
 If slope values is 0.5 or less, the release mechanism is “Fickian 
diffusion” and if 0.5˂n˂1 it follows “Non Fickian diffusion” (anomalous 
transport). The drug release follows zero order drug release and Non-Fickian 
case II transport if the values is 1. For the values of n higher than 1, the 
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mechanism of drug released is regarded as non-fickian case II transport. The 
model is used to analyse the release of pharmaceutical polymeric dosage 
forms when the release mechanism is not known or more than one type of 
release is involved. 
Effect of ‘n’ value for drug transport mechanism 
Release exponent (n) Drug transport mechanism 
n = 0.5 Fickian Diffusion 
0.5˂n˂1 Non-Fickian Diffusion 
n = 1 Case II transport 
n ˃ 1 Super case II transport 
 
STABILITY STUDIES 
The purpose of stability testing is to provide evidence on how the 
quality of a drug substance or drug product varies with time under the 
influence of a variety of environmental factors such as temperature, humidity 
and light, enabling recommended storage conditions, re-test periods and 
shelf-lives. Generally, the observation of the rate at which the product 
degrades under normal room temperature requires a long time. To avoid this 
undesirable delay, the principles of accelerated stability studies are adopted. 
ICH specifies the length of study and storage conditions. 
Long-Term Testing: 250 C ± 20 C / 60% RH ± 5% for 12 Months 
Accelerated Testing: 400 C ± 20 C /75% RH± 5% for 6 Months 
Stability studies were carried out at 400 C ± 200 C /75% RH ± 5% for all 
the formulations for a period of 1 month. 
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The selected formulations were closely packed in aluminium foils and 
then stored at 400 C ± 20 C /75% RH ± 5% in stability chamber for 1 month 
and evaluated for their physical appearance, drug content and in-vitro drug 
release studies at intervals of 15 days. 
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RESULTS AND DISCUSSION 
 
PREPARATION OF STANDARD CALIBRATION CURVE 
Determination of maximum absorption (λmax) of Ticagrelor  
The absorption maximum (λmax) of the Ticagrelor was estimated by 
scanning the drug solution (10µg/ml) between 200-400 nm regions on UV 
spectrophotometer. The obtained spectrum showed that the absorption 
maximum (λmax) was 295nm for the Ticagrelor. FIG.1 
 
Preparation of satandard calibration curve for Ticagrelor  
  The Standard Calibration curves of Ticagrelor were prepared using 
phosphate buffer pH6.8. The absorbance were measured at λmax of 295nm. 
The correlation coefficient was found to be 0.9987.  Ticagrelor obeys the 
beer’s law within the concentration range of (2-20µg/ml). Calibration plot of 
Ticagrelor in phosphate buffer pH6.8 was shown in FIG.2 and Table-1. 
 
DRUG EXCIPIENTS COMPATIBILITY STUDIES  
Fourier Transform Infrared (FTIR) Spectroscopic studies: 
FT-IR spectrum of the pure drug, and physical mixtures were recorded. 
Pure Ticagrelor spectra showed sharp characteristic peaks at 3383.14 cm-
1(O-H Str),3292.49cm-1(N-H Str), 1624.06 cm-1(C=C Str) 1585.49 cm-1(C=N 
Str)1517.98 cm-1 (N=N Str),1274.95 cm -1 (C-F Str). And the above 
characteristic peaks appear in the IR spectrum of pure drug and physical 
mixtures indicating that there were no modification or interaction between 
drug, carrier and diluents. (FIG.3, FIG.43)  
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Differential Scanning Calorimetric (DSC) Studies: 
DSC thermogram of the best formulation was recorded. Pure 
Ticagrelor exhibits a sharp endothermic peak at 142.5
0
C (FIG. 13). An 
endothermic peak corresponding to the melting point of pure drug was 
prominent in the physical mixtures (FIG. 44), which suggested clearly that 
there was no interaction between the drug and the diluents and the drug 
existed in its unchanged form. 
 
FORMULATION AND EVALUATION OF SOLID DISPERSION 
a. Formulation of Soild Dispersion 
In the present study, four formulations of Ticagrelor were prepared by 
using carrier PEG-6000 in the ratio of 1:1, 1:2, 1:3 and 1:4 by melting method. 
The prepared solid dispersions were found to be uniform and homogeneous 
in appearance (Table 2). 
 
b. Estimation of Percentage Yield: 
The percentage yield of all the formulations was determined by 
weighing the practical yield. Percentage yield is calculated for all the 
formulations. The percentage yield of solid dispersion ranged from 86.94% to 
96.22%. The percentage yield of the solid dispersion A4 was found to be high 
(96.22%) when compared to the other formulations. This indicates that there 
is no considerable loss in the yield during the mixing process. (Table 3) 
 
c. Determination of Drug Content: 
The drug content in all the formulations was estimated 
Spectrophotometrically at 295nm (Shimadzu UV1800, Japan). The drug 
content of the prepared solid dispersion was found to be in the range of 
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96.57% to 98.09% indicating the uniform distribution of drug in the 
formulation. (Table 3)  
 
d. In vitro Dissolution Studies: 
The cumulative percentage drug release profile data obtained for all 
solid dispersion formulations are tabulated in Table 4. The cumulative 
percentage of drug release of pure drug (Ticagrelor) at the end of one hour 
was found to be 21.93%. 
In melting method, PEG-6000 was used as a carrier. The release 
profiles of formulation in the ratios of 1:1, 1:2, 1:3, and 1:4 were found to be 
60.52%(A1), 67.78%(A2), 83.33%( A3), and 91.92 %( A4) after 1 hour (FIG. 
5) and Table 4. From the results, it was observed that A4 (1:4 ratio) exhibits 
maximum drug release of 91.92% and it was rated as the best formulation 
melting method using PEG-6000. 
 
Selection of Best Formulation: 
  The best formulation was selected based on the results obtained from 
the drug invitro release studies. In vitro dissolution studies revealed that there 
is marked increase in the dissolution rate of Ticagrelor solid dispersion when 
compared to pure drug. The A4 formulation (melting method) containing drug 
and PEG-6000 (1:4 ratio of Drug: carrier) showed higher dissolution rate of 
91.92% after 1hour, so it was considered as the overall best formulation. 
The order of drug release profile is Pure drug < Solid dispersion. 
The drug dissolution was increased in solid dispersion formulation. It 
happens because of the enhanced wettability, hydrophilic nature of the 
carriers and possibility of reduced crystallinity of the drug and conversion of 
amorphous form of the drug. 
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This study was planned to continue with best resultant product with 
crosspovidone, SSG and CCS as superdisintegrants and with different 
diluents and excipients to formulate sublingual tablets. The formula as on 
Table-5.1, 5.2. 
 
PREFORMULATION STUDY FOR SUBLINGUAL TABLETS: 
a. Angle of Repose: 
The angle of repose was used to determine the flow properties of 
powder blend. The angle of repose of the formulations ranged from 26˚.56’ to 
35˚.24’. The results of angle of repose for all the formulations were shown in 
Table 6 and FIG. 15. 
b. Bulk density: 
The bulk density is used as an index of the ability of the powder to flow. 
The bulk density of the formulations was in the range of 0.60 – 0.69 g/ml. The 
results of bulk density for all the formulations were shown in Table 6 and FIG. 
16. 
c. Tapped Density: 
The tapped density was used to access the free flowing properties of 
powder blend. The tapped density of all formulations were in the range of 
0.67-0.78 g/ml. The results of tapped density for all the formulations were 
shown in Table 6 and FIG.17. 
d. Carr’s Compressibility Index: 
The Carr’s compressibility index was used to determine the free 
flowing properties of powder blend. The compressibility index of all the 
formulations ranged from 9.71 -13.96%. The results of compressibility for all 
formulations were shown in Table 6 and FIG. 18. 
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e. Hausner’s Ratio: 
The Hausner’s ratio was an indirect index of ease of powder flow. The 
Hausner’s  ratio of all the formulations ranged from 1.11 – 1.18. This indicates 
better flow property of blend. The results of Hausner’s ratio for all the 
formulations were shown in Table 6 and FIG.19. 
 
FORMULATION OF TICAGRELOR FAST DISINTEGRATING  
SUBLINGUALTABLETS: 
The sublingual tablets of Ticagrelor was prepared by direct 
compression method using solid dispersion with different ratio (1.5%- 7.5%) 
of superdisintegrant (Crosspovidone, SSG and CCS) and with diluents 
(Mannitol) and microcrystalline cellulose. The compositions of the different 
formulation were given in Table-5.1, 5.2. Fifteen Formulations (F1 to F15) 
were prepared as per formula designed. All the tablets were white color and 
round in shape having 8 mm diameter. 
 
POST COMPRESSION EVALUATION: 
The prepared tablets were evaluated on various parameters such as 
thickness and diameter, hardness, weight variation, friability, uniformity 
content, wetting time, water absorption ratio, In-vitro disintegration time and 
In-vitro dissolution test. The results were summarized in Table 7, 8, and 9. 
 
a. General Appearance: 
The tablets were white coloured and round shaped. All tablets were 
elegant in appearance. 
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b. Thickness and Diameter: 
  The thickness and diameter of the formulations were used to 
determine the uniformity of size and shape of the tablets. From the results it 
was found that the thickness of the tablet in all formulation was 3.8 – 4 mm 
and the diameter of the tablet in all formulation was 8mm.The results 
indicated that all the formulations had uniform size and shape. The results 
were shown in Table 7. 
 
c. Hardness: 
           The hardness of the tablets was used to determine the resistance 
capacity of the tablets to chipping, abrasion or breakage under conditions of 
storage, transportation and handling before usage. The hardness of the 
tablets of all the formulations was found to be in the range of 2.8 – 4.0 
kg/cm2. The result indicated that all the tablets had a good mechanical 
strength. The results of the hardness for all the formulations were shown in 
Table 7. 
 
d. Weight Variation Test: 
The weight variation test was used to ensure the uniformity of the 
tablet in all formulations. The weight of all the tablets from each formulation 
was in the range from 199.9 mg to 202.2 mg. It was found all the tablets 
passed weight variation test, as the percentage weight variation was within 
the acceptable limits of 7.5%. The results were shown in Table 7. 
 
e. Friability test: 
Friability test was measured to ensure the mechanical strength of 
tablet. The results showed that the friability of all the formulation ranged from 
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0.51% to 0.65%. Friability of all the formulation was lesser than 1 % which 
indicated the tablets had a good mechanical resistance. The results were 
shown in Table 7. 
 
f. Uniformity of drug Content: 
The uniformity content test was used to determine the uniform amount 
of active ingredient present in all formulations. The drug content in the content 
uniformity of all the formulations was found to be in the range of 97.3 % - 98.9 
%. The results indicated all the formulations were within the acceptable limits 
as per USP limits. The results were shown in Table 7. 
 
g. In-vitro drug release Studies: 
 The dissolution profile range in 30 minutes was 51.1 % to 98.2 % 
(table 12). The maximum dissolution drug release rate was observed in 
combination of crospovidone (7.5%) with diluent (FIG. 25, 26, 27). The order 
of the dissolution rate with various superdisintegrants was found to be 
Crospovidone> SSG > CCS. 
 
h. Disintegration Time: 
 The in-vitro disintegration time was determined by 10ml class test 
tube apparatus. The results were shown in Table 8. Formulations F1, F2, F3, 
F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, and F15 showed the 
disintegration time obtained from 62.1 to 71.9 seconds respectively. It was 
observed that Formulation F10 containing Crospovidone (7.5%) and mannitol 
as diluent disintegrated rapidly in a short time (55.8 seconds). The results of 
disintegration of all the tablets were found to be lesser than 75 seconds. So 
all the formulation satisfied the criteria of fast dissolving sublingual tablets. 
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i. Water Absorption Ratio: 
The water absorption ratio test was used to ensure the capacity of the 
superdisintegrant and the diluent to absorb the water. The results of water 
absorption ratio of all the formulation were shown in Table 8. 
Formulations F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, 
F14 and F15 showed the water absorption ratio  43.2%, 44.2%, 45.5%, 47%, 
47.2%, 51.4%, 52.5%,  54.1%,  54.6%,  55.8%,  43.8%,  44.7%,  44.8%,  
45.3%, and 45.9% respectively. The results showed that as concentration of 
superdisintegrant increased water absorption ratio was also increased. 
Formulation F10 containing crosspovidone (7.5%) as superdisintegrant 
showed highest water absorption ratio (55.8 %) when compared to other 
formulations. The reason for high water absorption ratio for F10 formulation 
combined with the superdisintegrant action. Crosspovidone quickly wicks 
water in to the tablet to generate volume expansion. Crosspovidone uses 
combination of swelling and wicking. 
 
j.Wetting Time: 
Wetting time of the tablet was used to assess the capacity of the 
tablets to disintegrate by swelling in water. All the formulations showed quick 
wetting, this may be due to ability to swelling and also capacity of absorption 
of water. The results of wetting time of all the formulations were shown in 
Table 8. 
The formulations F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, 
F12, F13, F14 and F15 showed the wetting time, 68.1, 66.7, 61.6, 57.6, 55.8, 
66.6, 62.3, 58.8, 56.3, 54.3, 71.9, 70.9, 65.9, 61.2, 57.5 seconds respectively. 
The results indicated that the concentration of superdisintegrant influenced 
CHAPTER X                                                          RESULTS AND DISCUSSION 
 
Dept of Pharmaceutics, College of Pharmacy, MMC, Madurai-20 Page 130 
 
the wetting time. Formulation F10 containing crospovidone (7.5%) showed 
lesser wetting time than other formulations. 
This may be due to fact that superdisintegrant –Crospovidone 
performed its action by the combination of wicking and swelling action. 
Formulation F10 showed shorter wetting time. 
 
EFFECT OF DIFFERENT SUPERDISINTEGRANT ON RELEASE 
PROFILEOF TICAGRELOR SUBLINGUAL TABLETS: 
To study the effect of different superdisintegrant on release rate of 
ticagrelor sublingual  tablets, fifteen formulations (F1 to F15) were prepared 
by using CCS, Crosspovidone, SSG as superdisintegrant in various 
concentration (1.5%, 3%, 4.5%, 6%, 7.5%) with mannitol as diluents 
respectively. The formulated tablets were subjected to various quality tests 
and the release rates were shown in FIG. 25, 26 and 27. The dissolution data 
was presented in the Table 9. The invitro kinetics was presented in the Table 
11.1, 11.2. The dissolution rate followed first order kinetics as the graph 
between log cumulative % drug unreleased Vs time were found linear. 
 
SELECTION OF BEST FORMULATION: 
Among Fifteen formulations, the best was selected on the basis of 
lowest disintegration time, rapid drug release profile, higher water absorption 
ratio, short wetting time. Formulation F10 showed lowest disintegration time 
of 55.8 seconds, faster drug release rate of 98.2 %in 30 minutes, 
comparatively high water absorption ratio of 55.8 %, short wetting time of 54.3 
seconds and minimum chemicals composition. In these parameter would 
drive the F10 formulation as a best comparatively. 
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EVALUATION OF BEST FORMULATION 
Differential scanning calorimetric (DSC) Studies: 
Any possible drug polymer interaction can be studied by thermal 
analysis. The DSC thermogram of Ticagrelor exhibited an endothermic peak 
corresponding to its melting point. The thermogram of the final best 
formulation of ticagrelor with other excipients show the existence of drug 
endothermic peak within the range which indicated the absence of interaction 
between the drug and other excipients. The DSC thermogram of pure drug 
and the final best formulation is presented in FIG. 13 and 44. 
 
Fourier transform infrared (FTIR) spectroscopic Studies: 
Infrared spectra of the ticagrelor sublingual tablets showed major 
peaks at 3383.14 cm-
1
(O-H Str), 3292.49cm-
1
(N-H Str), 1624.06 cm-
1
(C=C 
Str) 1585.49 cm-
1
(C=N Str), 1517.98 cm-1(N=N Str) 1274.95 cm -1  (C-F Str) 
indicated that there was no interaction between the drug and the final 
formulation throughout the preparation of sublingual  tablets. The result was 
shown in FIG. 3, 43. 
 
Powder X-ray Diffraction Sudies: 
The diffractogram of Ticagrelor shows so many numbers of peaks, it 
indicates that the drug substance is crystalline in nature. From the 
diffractogram of solid dispersion of sublingual formulation, it was clearly 
evident that the intensity (heights) of peaks has been reduced significantly. 
This indicates that the percentage of crystallinity was reduced by solid 
dispersion. The enhancement in the rate of drug release from solid dispersion 
sublingual formulation is ascribed to the marked reduction in the crystallinity 
of Ticagrelor. FIG. 14, FIG. 45. 
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DRUG RELEASE KINETIC MODEL 
The drug release profiles of Ticagrelor sublingual tablets were fitted to 
various kinetic models such as Zero order, First order, Higuchi, Korsmeyer 
Peppas and Hixson-Crowell. In order to describe the kinetics of the release 
process of drug in all formulations, equations such as zero-order and first- 
order rate equations were used. Zero order rate equation describes the 
system where the release rate is independent of the concentrations of the 
dissolved species. While the first- order equation describes the release from 
systems where dissolution rate is dependent on the concentration of the 
dissolving species. It is evident from Table 11.1 and 11.2 that the drug 
release process is not zero order in nature. This indicates that the dissolution 
rate of the drug is not independent of the amount of drug available for 
dissolution and diffusion from the matrix. The dissolution data of all 
formulations when fitted in accordance with the first order equation it is 
evident that a linear relationship was obtained with ‘r’ (correlation coefficient) 
value close to unity and higher than ‘r’ obtained from zero order equation for 
all formulation (table), showing that the release is an apparent first order 
process. This indicates that the amount of drug released is dependent on the 
matrix.The obtained from invitro dissolution studies were fitted to zero –order, 
first-order and Korsmeyer Peppas equation. The first-order plots were found 
to be fairly linear as indicated by their high regression values. To confirm the 
exact mechanism of drug release, the data were fitted according to 
Korsmeyer Peppas equation: 
Mt/m∞= ktn 
where mt/m∞ is fraction of drug released, k is kinetic constant, t is release 
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time and n is the diffusional exponent for drug release. Peppas stated that the 
above equation could adequately describe the release of solutes from slabs, 
spheres, cylinders and discs, regardless of the release mechanism. The value 
of ‘n’ gives an indication of the release mechanism; when n =1, the release 
rate is independent of time (zero-order) (case II transport), n = 0.5 for Fickian 
diffusion and when 0.5 < n <1.0, diffusion and non-Fickian transport are 
implicated. Lastly, when n > 1.0 super case II transport is apparent. ’n’ is the 
slope value of log mt/m∞ versus log time curve. Slope values (n > 1.0) 
suggest that the release of ticagrelor from sublingual tablets followed 
Supercase-II transport suggesting that more than one mechanism may be 
involved in the release kinetics. The results were shown in table 11.1and 
11.2. 
STABILITY STUDIES: 
The optimized formulation F10 was evaluated for in-vitro drug release 
studies after keeping the tablets at accelerated stability conditions (400 
C/75%RH) for 1 months. It is evaluated initially,15 days and 1 month. In 15 
days time interval, the tablets were analysed for hardness, drug content, 
uniformity of weight, invitro disintegration time, % drug release. In-vitro drug 
release studies were performed in phosphate buffer pH 6.8 by using USP 
dissolution test apparatus-Type II, Rotating Paddle method. The results 
indicated that there was no significant change in in-vitro drug release studies. 
The data for in-vitro release profile was shown in Table No-13. 
TABLE-1: CALIBRATION OF TICAGRELOR IN PHOSPHATE BUFFER 
PH6.8 
 
 
S.No Concentration (µg/ml) Absorbance (nm) 
1 2 0.076 ± 0.011 
2 4 0.119 ± 0.011 
3 6 0.165 ± 0.009 
4 8 0.214 ± 0.023 
5 10 0.263 ± 0.025 
6 12 0.307 ± 0.029 
7 14 0.356 ± 0.037 
8 16 0.358 ± 0.056 
9 18 0.444 ± 0.057 
10 20 0.492 ± 0.069 
 
N=3*    REGRESSION VALUE = 0.9986 ± 0.0006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE-2: COMPOSITION OF SOLID DISPERSION 
 
S.No 
Formulation 
code 
Method Ratio 
Composition 
1 M1 Melting 1:1 
Drug:PEG-6000 
2 M2 Melting 1:2 
Drug:PEG-6000 
3 M3 Melting 1:3 
Drug:PEG-6000 
4 M4 Melting 1:4 
Drug:PEG-6000 
 
 
TABLE-3: PERCENTAGE OF YEILD AND DRUG CONTENT OF 
TICAGRELOR SOLID DISPERSION 
 
 
S.No 
Formulation 
Code 
Method Ratio 
Percentage of 
yield ± SD 
Drug content 
± SD 
1 A1 Melting 1 : 1 86.94 ± 0.34 96.57 
2 A2 Melting 1 : 2 89.05 ± 0.34 96.95 
3 A3 Melting 1 : 3 90.61 ± 0.41 97.71 
4 A4 Melting 1 : 4 96.22 ± 0.63 98.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE-4: CUMULATIVE PERCENTAGE DRUG RELEASE 
OFTICAGRELOR SOLID DISPERSION USING PEG-6000 CARRIER BY 
MELTING METHOD 
 
 
 
Time 
(min) 
Percentage drug release ± SD 
A1 
 
1:1 
A2 
 
1:2 
A3 
 
1:3 
A4 
 
1:4 
 
Pure drug 
 
10 
22.14±1.89 25.15±1.26 25.23±1.04 28.89±1.73 06.31±1.44 
 
20 
31.43±1.07 34.83±1.71 44.60±0.37 48.76±0.66 11.63±1.22 
 
30 
38.53±1.87 40.54±0.82 70.92±1.07 65.85±1.30 14.42±0.28 
 
40 
44.18±1.53 47.43±1.30 74.23±1.59 74.01±1.08 17.45±0.88 
 
50 
56.13±1.20 57.20±1.55 78.23±1.23 85.75±1.32 19.49±0.47 
 
60 
60.52±0.83 67.78±1.09 83.33±1.30 91.92±1.26 21.93±0.76 
N=3* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE-5.1: TICAGRELOR SUBLINGUAL TABLET FORMULATIONS 
 
 
Ingredients 
(mg) 
Formulation code 
F1 F2 F3 F4 F5 F6 F7 
Solid dispersion 
equivalent to 6mg 
ticagrelor 
30 30 30 30 30 30 30 
Crosscarmellose 
sodium 
3 6 9 12 15 - - 
Crosspovidone - - - - - 3 6 
SSG - - - - - - - 
MCC 102 43 40 37 34 31 43 40 
Mannitol 120 120 120 120 120 120 120 
Saccharin sodium 1 1 1 1 1 1 1 
Magnesium 
stearate 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE-5.2: TICAGRELOR SUBLINGUAL TABLET FORMULATIONS 
 
 
Ingredients 
(mg) 
Formulation code 
F8 F9 F10 F11 F12 F13 F14 F15 
Solid dispersion 
equivalent to 6mg 
ticagrelor 
30 30 30 30 30 30 30 30 
Crosscarmellose 
sodium 
- - - - - - - - 
Crosspovidone 9 12 15 - - - - - 
SSG - - - 3 6 9 12 15 
MCC 102 37 34 31 43 40 37 34 31 
Mannitol 120 120 120 120 120 120 120 120 
Saccharin sodium 1 1 1 1 1 1 1 1 
Magnesium 
stearate 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE-6: PRECOMPRESSION EVALUATION SUBLINGUAL 
FORMULATIONS 
 
 
Formulation 
code 
Angle of 
repose (Ɵ) 
Bulk 
density 
(g/cm3) 
Tapped 
density 
(g/cm3) 
Hausner’s 
ratio 
Carr’s 
index 
(%) 
F1 34.73 ± 1.96 0.66 ± 0.038 0.73± 0.025 1.14 ± 0.098 12.38 
F2 34.17 ± 1.02 0.61 ± 0.030 0.69± 0.024 1.13 ± 0.031 12.06 
F3 
33.71 ±  
1.96 
0.66 ± 0.073 
0.75 ± 
0.076 
1.14 ± 0.025 12.81 
F4 33.79 ± 1.85 0.69 ± 0.021 
0.78 ± 
0.028 
1.13 ± 0.005 11.62 
F5 30.95 ± 0.22 0.64 ± 0.020 
0.72 ± 
0.025 
1.11 ± 0.004 10.69 
F6 34.24 ± 1.88 0.63 ± 0.019 
0.70 ± 
0.034 
1.11 ± 0.002 09.71 
F7 34.83 ± 1.04 0.60 ± 0.010 
0.67 ± 
0.023 
1.12 ± 0.070 10.84 
F8 32.54 ± 1.30 0.60 ± 0.031 
0.68 ± 
0.024 
1.13 ± 0.004 10.67 
F9 31.39 ± 0.59 0.61 ± 0.010 
0.68 ± 
0.024 
1.12 ± 0.072 10.93 
F10 26.56 ± 0.62 0.63 ± 0.033 
0.72 ± 
0.025 
1.13 ± 0.029 12.22 
F11 35.24 ± 0.76 0.63 ± 0.037 
0.72 ± 
0.024 
1.14 ± 0.037 12.32 
F12 35.74 ± 0.55 0.63 ± 0.018 
0.73 ± 
0.025 
1.18 ± 0.062 13.79 
F13 33.98 ± 1.25 0.60 ± 0.036 
0.71 ± 
0.024 
1.18 ± 0.066 15.35 
F14 30.88 ± 0.90 0.63 ± 0.041 
0.71 ± 
0.065 
1.12 ± 0.043 11.20 
F15 30.01 ± 0.62 0.61 ± 0.017 
0.70 ± 
0.047 
1.16 ± 0.004 13.96 
N=3* 
 
 
 
 
 
 
TABLE-7: POST COMPRESSION EVALUATION OF TICAGRELOR 
SUBLINGUAL TABLETS 
 
Formulation 
code 
Hardness 
(kg/cm2) ± 
SD 
Thickness 
(mm) ± SD 
Friability 
± SD 
(%) 
Weight 
variation 
(mg) ± SD 
Drug 
content  
(%)  ± SD 
F1 3.4± 0.15 3.9 ± 0.05 0.5 ± 0.05 201.3 ± 0.75 98.38 ± 0.34 
F2 3.4 ± 0.05 3.9 ± 0.05 0.5 ± 0.04 201.3 ± 1.23 98.17 ± 0.60 
F3 3.2 ± 0.05 3.9 ± 0.11 0.5 ± 0.04 200.4 ± 0.80 98.37 ± 0.69 
F4 3.3 ± 0.23 3.8 ± 0.05 0.5 ± 0.05 200.5 ± 1.56 97.77 ± 0.35 
F5 3.2 ± 0.15 3.7 ± 0.05 0.6 ± 0.03 199.9 ± 1.01 97.97 ± 0.35 
F6 4.0 ± 0.20 3.8 ± 0.05 0.5 ± 0.02 201.0 ± 0.60 98.58 ± 0.69 
F7 3.0 ± 0.11 3.7 ± 0.11 0.5 ± 0.01 201.6 ± 0.49 97.97 ± 0.69 
F8 2.8 ± 0.05 3.8 ± 0.05 0.6 ± 0.01 201.0 ± 0.76 98.18 ± 0.00 
F9 3.1 ± 0.23 3.8 ± 0.17 0.6 ± 0.01 201.3 ± 0.51 98.17 ± 1.05 
F10 3.7 ± 0.40 4.0 ± 0.05 0.4 ± 0.06 201.3 ± 0.15 98.98 ± 0.35 
F11 3.5 ± 0.10 3.9 ± 0.17 0.6 ± 0.02 201.9 ± 0.40 98.38 ± 0.92 
F12 3.2 ± 0.25 4.0 ± 0.05 0.5 ± 0.01 201.2 ± 0.46 98.78 ± 0.60 
F13 3.3 ± 0.05 3.8 ± 0.10 0.5 ± 0.06 202.3 ± 0.45 97.97 ± 0.92 
F14 3.2 ± 0.10 4.0 ± 0.10 0.5 ± 0.02 200.3 ± 0.20 97.57 ± 0.61 
F15 3.1 ± 0.05 3.9 ± 0.10 0.6 ± 0.02 202.4 ± 0.55 97.36 ± 0.35 
N=3* 
 
 
 
 
 
 
 
 
TABLE-8: POST COMPRESSION EVALUATION OF TICAGRELOR 
SUBLINGUAL TABLETS 
 
Formulation 
code 
Wetting time 
(sec) 
Water 
absorption ratio 
(%) 
Disintegration 
time (sec) 
F1 68.1 ± 0.27 43.2 ± 0.44 66.8 ± 0.80 
F2 66.7 ± 0.41 44.2 ± 0.54 65.9 ± 0.55 
F3 61.6 ± 0.51 45.5 ± 0.59 64.5 ± 0.50 
F4 57.6 ± 0.44 47.04 ± 0.26 63.1 ± 0.56 
F5 55.8 ± 0.67 47.2 ± 0.52 61.9 ± 0.90 
F6 66.6 ± 0.96 51.4 ± 0.75 64 ± 0.07 
F7 62.3 ± 0.60 52.5 ± 0.22 62.9 ± 0.17 
F8 58.8 ± 0.25 54.1 ± 0.32 62.1 ± 0.65 
F9 56.3 ± 0.57 54.6 ± 0.12 60.7 ± 0.36 
F10 54.3 ± 0.28 55.8 ± 0.40 55.8 ± 0.80 
F11 71.9 ± 0.22 43.8 ± 0.20 71.9 ± 0.90 
F12 70.9 ± 0.55 44.7 ± 0.35 70.3 ± 0.55 
F13 65.9 ±0.40 44.8 ± 0.19 68.4 ± 0.36 
F14 61.2 ± 0.23 45.3 ± 0.22 66.1 ± 1.00 
F15 57.5 ± 0.50 45.9 ± 0.20 62.5 ± 0.86 
 N=3* 
 
 
 
 
 
 
 
 
TABLE-9: INVITRO RELEASE PROFILE OF TICAGRELOR SUBLINGUAL 
TABLETS 
 
Formulation 
code 
Time 
5 min 10 min 15 min 20 min 25 min 30 min 
F1 52.4±0.66 74.2±0.66 79.9±0.66 83.1±0.43 86.1±0.87 88.9±0.66 
F2 57.2±1.09 74.1±0.66 78.1±1.64 83.2±3.08 88.2±1.52 91.8±1.99 
F3 56.6±1.09 76.5±0.43 81.5±2.19 86.1±0.87 89.31.32± 92.4±0.66 
F4 58.2±0.88 78.3±0.87 84.2±0.66 87.9±0.43 91.2±0.25 94.7±0.50 
F5 59.2±0.66 79.2±0.87 85.1±0.66 88.9±0.67 92.4±0.66 95.6±0.90 
F6 53.7±0.66 75.2±0.87 80.9±0.75 84.4±0.87 87.0±0.87 90.0±0.43 
F7 59.4±0.50 79.2±0.87 86.1±0.87 89.2±0.87 92.5±0.25 94.1±1.64 
F8 60.1±0.66 80.0±0.87 86.0±0.66 89.7±0.67 93.4±0.66 96.4±0.90 
F9 61.0±0.67 81.0±1.09 87.0±0.43 90.9±0.43 94.7±0.66 97.7±0.67 
F10 61.4±1.09 79.3±1.09 85.7±1.15 90.5±0.87 94.5±0.67 98.2±0.67 
F11 51.1±0.67 72.8±0.67 78.7±1.15 81.8±0.00 83.9±0.43 87.4±0.43 
F12 52.0±0.66 73.5±0.86 79.2±0.86 82.2±0.43 84.8±0.43 88.0±0.67 
F13 52.8±0.90 75.4±1.09 80.2±1.09 83.4±0.90 86.6±0.43 89.2±0.87 
F14 54.3±2.42 71.6±1.32 75.2±1.15 84.2±1.52 87.6±1.32 90.9±1.30 
F15 58.4±0.90 78.3±0.87 85.1±1.09 88.2±0.90 91.5±0.66 93.7±0.67 
N=3* 
 
 
 
 
 
 
TABLE-10.COMPARISION OF INVITRO RELEASE OF PURE DRUG, 
CONVENTIONAL TABLET, TICAGRELOR SUBLINGUAL TABLETS 
 
TIME PURE DRUG 
CONVENTINAL 
TABLET 
SUBLINGUAL 
TABLETS 
5 06.11±0.79 13.32±0.91 61.4±1.09 
10 11.17±0.69 24.21±0.78 79.3±1.09 
15 14.96±0.35 37.42±0.56 85.7±1.15 
20 17.48±0.06 45.78±0.91 90.5±0.87 
25 19.43±0.05 53.97±0.88 94.5±0.67 
30 21.95±0.16 61.20±0.76 98.2±0.67 
TABLE-11.1: INVITRO RELEASE KINETICS DATA OF TICAGRELOR SUBLINGUAL TABLETS 
 
 
Formulation 
code 
Zero order First order Higuchi 
Korsmeyer 
peppas 
Hixon crowell 
r2 K0(h-1) r2 K1(h-1) r2 KH(h-1/2) r2 n r2 KHC(h-1/3) 
F1 0.702 2.456 0.894 -0.029 0.920 10.44 0.825 1.260 0.831 -0.071 
F2 0.704 2.475 0.962 -0.036 0.924 11.15 0.816 1.251 0.875 -0.079 
F3 0.693 2.515 0.926 -0.038 0.919 11.38 0.819 1.263 0.884 -0.076 
F4 0.690 2.569 0.952 -0.043 0.916 12.06 0.818 1.272 0.879 -0.085 
F5 0.688 2.591 0.961 -0.031 0.917 11.79 0.817 1.273 0.897 -0.091 
F6 0.693 2.471 0.927 -0.040 0.918 10.81 0.823 1.261 0.832 -0.073 
F7 0.675 2.562 0.949 -0.047 0.908 12.43 0.820 1.260 0.837 -0.082 
F8 0.686 2.612 0.966 -0.053 0.914 12.30 0.817 1.276 0.891 -0.068 
N=3* 
 
 
 
TABLE-11.2: INVITRO RELEASE KINETICS OFTICAGRELOR SUBLINGUAL TABLETS 
 
 
Formulation 
code 
Zero order First order Higuchi 
Korsmeyer 
peppas 
Hixon crowell 
R2 K0(h-1) R2 K1(h-1) R2 KH(h-1/2) R2 n R2 KHC(h-1/3) 
F9 0.686 2.647 0.977 -0.053 0.915 12.45 0.819 1.263 0.902 -0.095 
F10 0.699 2.657 0.955 -0.055 0.922 12.12 0.814 1.277 0.936 -0.102 
F11 0.697 2.407 0.889 -0.027 0.920 10.16 0.818 1.251 0.829 -0.068 
F12 0.695 2.418 0.919 -0.028 0.918 10.42 0.820 1.273 0.825 -0.069 
F13 0.675 2.425 0.923 -0.031 0.916 10.72 0.823 1.258 0.874 -0.077 
F14 0.733 2.514 0.974 -0.035 0.941 09.06 0.827 1.259 0.947 -0.088 
F15 0.681 2.552 0.981 -0.042 0.912 12.06 0.816 1.270 0.921 -0.099 
TABLE-12: STABILITY STUDY FOR BEST FORMULATION 
 
N=3* 
 
 
 
 
 
 
 
 
 
 
 
 
TEMPERATURE DAYS 
DRUG CONTENT 
(%) 
HARDNESS IN 
Kg/cm2 
DISINTEGRATION 
TIME IN SEC 
DRUG RELEASE 
250C 
15 98.78±0.35 3.81±0.05 40.26±1.41 97.97±0.35 
30 98.58±0.34 3.85±0.01 52.03±0.73 97.77±0.35 
400C/75% RH 
15 97.97±0.35 3.88±0.01 44.30±0.81 97.36±0.35 
30 97.77±0.34 4.06±0.11 47.30±0.95 97.16±0.35 
TABLE-13: INVITRO DRUG RELEASE OF STABILITY STUDIES FOR THE BEST FORMULATION (F10) 
 
TIME IN 
MINUTES 
CONTROL 
250C (Room Temperature) 400C / 75% RH 
15th day 30th day 15th day 30th day 
5 61.44±1.09 61.30±0.98 62.60±1.09 60.43±0.79 60.67±0.88 
10 79.35±1.09 80.51±0.78 79.20±1.03 78.33±0.78 78.17±0.97 
15 85.73±1.15 87.04±0.87 85.30±0.98 84.86±0.94 84.63±1.09 
20 90.52±0.87 89.65±0.89 90.52±0.88 91.39±0.38 88.31±1.09 
25 94.58±0.66 94.44±0.86 95.31±0.86 94.00±0.75 94.03±0.59 
30 98.21±0.66 97.48±1.03 97.79±0.95 97.35±0.57 97.31±0.83 
 
 
 
 
 
 
FIG.1: DETERMINATION OF λ MAX FOR TICAGRELOR  
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Fig.2: calibration curve of ticagrelor in phosphate buffer 
pH6.8
Series1
Linear (Series1)
 
 
 
FIG.3: FT-IR SPECTRUM OF TICAGRELOR PURE DRUG 
 
 
 
FIG.4: FT-IR SPECTRUM OF SODIUM STARCH GLYCOLATE 
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FIG.5: FTIR SPECTRUM OF SSG+TICAGRELOR 
 
 
 
FIG.6: FT-IR SPECTRUM OF CROSSCARMELLOSE SODIUM 
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FIGURE.7: FT-IR SPECTRUM OF CCS+TICAGRELOR 
 
 
 
FIGURE.8: FT-IR SPECTRUM OF CROSSPOVIDONE 
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FIGURE.9: FT-IR SPECTRUM OF CROSSPOVIDONE + TICAGRELOR 
 
 
FIGURE.10: FT-IR SPECTRUM OF MICROCRYSTALLINE CELLULOSE 
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FIGURE.11: FT-IR SPECTRUM OF MCC 102 + TICAGRELOR 
 
 
FIGURE.12:FT-IR SPECTRUM OF TICAGRELOR SOLID DISPERSION 
 
 
 
 
400600800100014001800240032004000
1/cm
-2.5
0
2.5
5
7.5
10
12.5
15
%T
3
9
7
3
.3
6
3
9
5
9
.8
6
3
8
6
3
.4
2
3
8
3
0
.6
3
3
8
1
7
.1
3
3
7
7
0
.8
4
3
6
8
5
.9
7
3
5
2
5
.8
8
3
4
6
9
.9
4
3
4
4
4
.8
7
3
4
1
9
.7
9
3
4
0
6
.2
9
3
3
9
0
.8
6
3
3
8
3
.1
4
3
3
6
5
.7
8
3
3
4
8
.4
2
3
3
2
5
.2
8
3
3
0
9
.8
5
3
2
7
5
.1
3
3
2
5
3
.9
1
3
2
2
1
.1
2
3
1
9
6
.0
5
3
1
6
9
.0
4
3
1
3
4
.3
3
3
0
9
9
.6
1
3
0
8
0
.3
2
3
0
4
5
.6
0
2
9
5
3
.0
2
2
9
2
7
.9
4
2
8
9
9
.0
1
2
6
8
6
.8
4
2
6
6
7
.5
5
2
6
4
0
.5
5
2
6
2
3
.1
9
2
5
3
2
.5
4
2
5
1
5
.1
8
2
4
9
5
.8
9
2
4
7
8
.5
3
2
4
6
5
.0
3
2
4
4
5
.7
4
2
4
2
8
.3
8
2
4
0
9
.0
9
2
3
8
7
.8
7
2
3
5
3
.1
6
2
3
0
1
.0
8
2
2
2
0
.0
7
2
1
9
1
.1
3
2
0
8
8
.9
1
2
0
6
5
.7
6
2
0
4
2
.6
2
2
0
1
7
.5
4
2
0
0
5
.9
7
1
8
5
1
.6
6
1
8
4
2
.0
2
1
6
5
8
.7
8
1
5
3
5
.3
4
1
4
9
2
.9
0
1
4
3
1
.1
8
1
3
8
1
.0
3
1
2
9
0
.3
8
1
2
3
0
.5
8 1
1
7
0
.7
9 1
1
1
6
.7
8
1
0
7
6
.2
8
1
0
1
8
.4
1
1
0
0
2
.9
8
9
3
3
.5
5
8
9
4
.9
7
8
4
6
.7
5
7
3
6
.8
1
6
4
6
.1
5 6
2
6
.8
7
5
7
6
.7
2
5
1
8
.8
5
5
0
3
.4
2
4
8
6
.0
6
4
7
2
.5
6
4
5
9
.0
6
4
3
5
.9
1
4
1
8
.5
5
400600800100014001800240032004000
1/cm
-5
0
5
10
15
20
25
%T
3
9
3
4
.7
8
3
9
0
7
.7
8
3
8
5
3
.7
7
3
8
4
2
.2
0
3
7
7
2
.7
6
3
7
6
1
.1
9
3
7
1
2
.9
7
3
6
9
3
.6
8
3
6
8
0
.1
8
3
5
2
7
.8
0
3
3
8
5
.0
7
3
2
9
2
.4
9
3
1
8
4
.4
8
2
8
8
5
.5
1
2
7
4
0
.8
5
2
3
6
0
.8
7
1
6
8
9
.6
4
1
6
2
5
.9
9
1
6
1
8
.2
8
1
5
8
5
.4
9
1
5
6
2
.3
4
1
5
1
7
.9
8
1
5
0
0
.6
2
1
4
2
5
.4
0
1
2
7
6
.8
8 9
6
2
.4
8 7
7
1
.5
3
6
5
9
.6
6
tica solid dispersion
 
 
 
FIGURE.13: DSC THERMOGRAM OF TICAGRELOR PURE DRUG 
 
 
FIGURE.14: PXRD PATTERN OF TICAGRELOR PURE DRUG 
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FIGURE.43: FTIR SPECTRUM OF TICAGRELOR SUBLINGUAL BEST 
FORMULATION (F10) 
 
 
FIGURE.44: DSC THERMOGRAM FOR TICAGRELOR SUBLINGUAL BEST 
FORMULATION 
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FIGURE.45: PXRD PATTERN OF TICAGRELOR SUBLINGUAL BEST 
FORMULATION (F10) 
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SUMMARY AND CONCLUSION 
 
SUMMARY 
The aim of the present study was to develop oral sublingual tablets of 
ticagrelor to give quick onset of action by rapidly disintegrating in a few 
seconds without the need of water with better patient compliance. In such 
cases, bioavailability of drug is significantly greater and adverse event is 
reduced than those observed from conventional tablet dosage form. 
 
The work done is summarized as follows: 
 Ticagrelor is very slightly soluble in water; so the study plan was 
done, to improve the solubility of ticagrelor by solid dispersion, and 
then was to formulate sublingual tablets. 
 Solid dispersion was prepared by melting method using water soluble 
carrier polyethylene glycol 6000 showed better in vitro release studies 
in phosphate buffer pH6.8 using USP Type II apparatus. 
 The results revealed that the increase in the carrier concentration 
increased the dissolution rate (1:4 ratios). 
 The in vitro release studies revealed that the solid dispersion 
formulations showed a faster drug release when compared to the 
physical mixture and pure drug. 
 By performing Drug - Excipients compatibility studies by IR 
spectrophotometry, no interaction drug-excipients was confirmed. Oral 
disintegrating tablets were formulated by direct compression method 
and suitable analytical method based on UV-Visible spectrophotometer 
was developed for the model drug  
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 Standard calibration curve prepared to determine the drug content in 
the prepared tablets and UV analysis was performed to determine the 
drug during in vitro release studies. 
 Prior to compression, the blend of drug and excipients were evaluated 
for flow properties such as Angle of repose, loose bulk density, Tapped 
density, % Compressibility, and Hausner’s ratio. All the formulations 
showed good flow properties. 
 Sublingual tablets were prepared by direct compression technique 
using 12-Station D/B Tooling Compression Machine, equipped with 
concave round punch of 8 mm diameter. 
 Post compression evaluation of prepared sublingual tablets were 
carried out with the help of different pharmacopoeial tests.  
 The shape and colour of all the formulations were found to be circular 
and white in colour.  
 The thickness was found to be uniform in specific formulations. The 
hardness, weight variation, diameter are also within the permitted 
limits.  
 The friability of all the tablets was found to be ˂ 1%, which indicates 
the good mechanical resistance. 
 The wetting time of sublingual tablets containing crosspovidone (7.5%) 
was found to be 54 seconds. 
CONCLUSION 
The study conclusively demonstrated significant results for ticagrelor 
sublingual tablets. The sublingual tablets of ticagrelor was more palatable, 
and it is mostly helpful to the patients for the treatment of acute coronary 
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syndrome, cardiac angina. The sublingual tablets of ticagrelor can be 
successfully prepared by direct compression method using selected 
superdisintegrants with Crosscarmellose sodium 1.5%, 3%, 4.5%, 6%, 7.5%, 
Crosspovidone 1.5%, 3%, 4.5%, 6%, 7.5% and Sodium starch glycolate 
1.5%, 3%, 4.5%, 6%, 7.5% for the better patient compliance and effective 
therapy the relative efficiency to improve the disintegration and dissolution 
rate of tablets were found. The disintegration time of F10 with 7.5% 
Crosspovidone formulation to be as 55.8 seconds respectively and is almost 
better than other formulations.  Invitro dissolution studies were performed for 
all formulations. The formulation F10 showed 98.21% release within the 30 
minutes. Crosspovidone shows good result as compare to other 
superdisintegrants. 
Crosspovidone > crosscarmellose sodium > sodium starch glycolate 
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